Clinical Development  
AIN457/ secukinumab 
Clinical 
Trial 
Protocol CAIN457A2304E1 / [STUDY_ID_REMOVED] 
A multicenter, d ouble -blind and open label, [ADDRESS_604590] s with moderate to severe chronic 
plaque -type psoriasis treated with either a fixed dose 
regimen or on a r etreatment a t start of relapse regimen 
Authors:   
Document type:  Amended Protocol Version  
EUDRACT number:  2012 -000985 -39 
Version number:  v02 Clean  
Development phase:  III 
Release date:  29-Apr-[ADDRESS_604591] of abbreviations ............................................................................................................ 6 
Glossary of terms  ................................................................................................................. 8 
Amendment 2 ........................................................................................................................... 10 
Amendment 1, 25- Apr-2014..................................................................................................... 12 
Protocol synopsis ............................................................................................................... 14 
1 Introduction ....................................................................................................................... 18 
1.1 Background ............................................................................................................ 18 
1.2 Purpose .................................................................................................................. 18 
2 Study objectives ................................................................................................................. 19 
2.1 Primary and key secondary objectives .................................................................. 19 
2.2 Secondary objectives ............................................................................................. 19 
2.3 Exploratory objectives ........................................................................................... 20 
3 Investigational plan  ........................................................................................................... 20 
3.1 Study design........................................................................................................... 20 
3.2 Rationale of study design  ....................................................................................... 23 
3.3 Rationale of dose/regimen, route of administration and duration of treatment ..... 24 
3.4 Rationale for choice of comparator ....................................................................... 24 
3.5 Purpose and timing of interim analyses/design adaptations .................................. [ADDRESS_604592]- study treatment .......................................... 39 
5.5.12  Early study termination  ......................................................................... 39 
6 Visit schedule and assessments  ......................................................................................... 39 
6.1 Information to be collected on screening failures .................................................. 47 
6.2 Patient demographics/other baseline characteristics  ............................................. 47 
6.3 Treatment exposure and compliance  ..................................................................... 47 
6.4 Efficac y .................................................................................................................. 47 
6.4.1  Investigator’s global assessment (IGA mod 2011) ............................... 48 
6.4.2  Assessment of the psoriasis area and severity index (PASI) ................ 48 
6.4.3  Appropriateness of efficacy assessments  .............................................. 51 
6.5 Safety  ..................................................................................................................... 51 
6.5.1  Physical examination  ............................................................................ 51 
6.5.2  Vital signs .............................................................................................. 52 
6.5.3  Height and weight ................................................................................. 52 
6.5.4  Laboratory evaluations  .......................................................................... 52 
6.5.5  Electrocardiogram (ECG)  ..................................................................... 54 
6.5.6  Pregnancy and assessments of fertility  ................................................. 54 
6.5.7  Appropriateness of safety measurements  .............................................. 54 
6.6 Other assessments  .................................................................................................. 54 
6.6.1  Fasting laboratory evaluations .............................................................. 55 
6.6.2  Resource utilization  ............................................................................... 55 
6.6.3  Health -related Quality of Life  ............................................................... 55 
6.6.4  Pharmacokinetics  .................................................................................. 57 
  58 
6.6.6  Other biomarkers ................................................................................... 58 
7 Safety monitoring  .............................................................................................................. 59 
7.1 Adverse events  ....................................................................................................... 59 

[COMPANY_001]  Confidential  Page 4 
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
7.2 Serious adverse event reporting ............................................................................. 61 
7.3 Liver safety monitoring  ......................................................................................... 62 
7.4 Pregnancy reporting  ............................................................................................... 62 
7.5 Prospective suicidality assessment  ........................................................................ 63 
8 Data review and database management  ............................................................................. 63 
8.1 Site monitoring  ...................................................................................................... 63 
8.2 Data collection  ....................................................................................................... 63 
8.3 Database management and quality control  ............................................................ 64 
8.4 Data Monitoring Committee  .................................................................................. 64 
8.5 Adjudication Committee  ........................................................................................ 64 
9 Data analysis  ...................................................................................................................... 64 
9.1 Analysis sets  .......................................................................................................... 65 
9.2 Patient demographics and other baseline characteristics  ....................................... 65 
9.3 Treatments  ............................................................................................................. 66 
9.4 Analysis of the primary and key secondary variable(s) ......................................... 66 
9.4.1  Variable(s)  ............................................................................................. 66 
9.4.2  Statistical model, hypothesis, and method of analysis  .......................... 66 
9.4.3  Handling of missing values/censoring/discontinuations ....................... 67 
9.4.4  Supportive analyses ............................................................................... 67 
9.5 Analysis of secondary variables ............................................................................ 67 
9.5.1  Efficacy variables  .................................................................................. 67 
9.5.2  Safety variables  ..................................................................................... 68 
9.5.3  Resource utilization  ............................................................................... 69 
9.5.4  Health -related Quality of Life  ............................................................... 69 
9.5.5  Pharmacokinetics  .................................................................................. 70 
  70 
9.5.7  Biomarkers  ............................................................................................ 71 
9.5.8  PK/PD  ................................................................................................... 71 
9.6 Interim analyses  ..................................................................................................... 71 
9.7 Sample size calculation  .......................................................................................... 71 
10 Ethical considerations ........................................................................................................ 71 
10.1  Regulatory and ethical compliance ........................................................................ 71 
10.2  Informed consent procedures ................................................................................. 72 
10.3  Responsibilities of the investigator and IRB/IEC  .................................................. 72 
10.4  Publication of study protocol and results............................................................... 72 
11 Protocol adherence  ............................................................................................................ 72 

[COMPANY_001]  Confidential  Page 5 
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
11.1  Protocol Amendments ........................................................................................... 73 
12 References  ......................................................................................................................... 73 
13 Appendix 1: Clinically notable laboratory values and vital signs ..................................... 75 
14 Appendix 2: Liver event definitions and follow-up requirements .................................... 76 
15 Appendix 3: Blood collection log for pharmacokinetics (PK) and immunogenicity 
(IG) .................................................................................................................................... 79 
16 Appendix 4: Pharmacokinetics (PK) and immunogenicity (IG) sample labeling information  ........................................................................................................................ [ADDRESS_604593]    aspartate aminotransferase 
CHMP             the European Union Committee for Medicinal Products for Human Use 
CRF    Case Report/Record Form (paper or electronic)  
CPO    Country Pharma Organization 
CRO    Contract Research Organization  
CS   Corticosteroid (s) 
DLQI    Dermatology Life Quality Index© 
DMC    Data Monitoring Committee  
DS&E    Drug Safety & Epi[INVESTIGATOR_471707]-5D   Euro -QoL 5 -Dimension Health© Questionnaire  
ICH International Conference on Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Human Use  
HAQ    Health Assessment Questionnaire 
HAQ- DI  Health Assessment Questionnaire- Disability Index  
IEC   Independent Ethics Committee 
IGA   Investigator’s Global Assessment 
IGA mod 2011  [COMPANY_001] Invetigator’s global assessment modified [ADDRESS_604594]  
IRT   Interactive Response Technology 
i.v.   intravenous MedDRA   Medical Dictionary for Regulatory Activities  
OC/RDC   Oracle Clinical/Remote Data Capturing  
PASI    Psoriasis Area and Severity Index  
PD   Pharmacodynamic (s)  
PFS   Pre-filled syringe  
[COMPANY_001]  Confidential  Page 7 
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
PK   Pharmacokinetic (s)  
PsA   Psoriatic Arthritis  
PUVA   Psoralen+UVA treatment  
SAE    serious adverse event  
s.c.   Subcutaneous 
SoR   Start of Relapse  
VAS    visual analog scale  
[COMPANY_001]  Confidential  Page 8 
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
Glossary of terms 
 
Assessment  A procedure used to generate data required by [CONTACT_471719](s) used as a comparator to reduce assessment bias, 
preserve blinding of investigational drug, assess internal study validity, and/or evaluate comparative effects of the investigational 
drug 
Enrollment  Point/time of patient entry into the study; the point at which informed consent must be obtained (i.e. prior to starting any of 
the procedures described in the protocol)  
Epoch  The planned stage of the subjects’ participat ion in the study. 
Each epoch serves a purpose in the study as a whole. Typi[INVESTIGATOR_144914]: determination of subject eligibility, wash- out of 
previous treatments, exposure of subject to treatment or to 
follow -up on subjects after treatment has ended.  
Inves tigational drug  The drug whose properties are being tested in the study; this definition is consistent with US CFR 21 Section 312.3 and is synonymous with “investigational new drug” or “investigational 
medicinal product.”  
Investigational treatment  All inv estigational drug(s) whose properties are being tested in 
the study as well as their associated treatment controls.  
This includes  any placebos, any active controls, as well as 
approved drugs used outside of their indication/approved dosage or tested in a fixed combination.  
Investigational treatment generally does not include other 
treatments administered as concomitant background therapy required or allowed by [CONTACT_213734]/dosage  
Medication number  A unique identifier on the label of each investigational/study drug package in studies that dispense medication using an IRT 
system  
Subject Number  A number assigned to each patient who enrolls into the study  
Part  A subdivision of a single protocol into major design components. 
These parts often are independent of each other and have different populations or objectives. For example, a single dose design, a multiple dose design that are combined into one protocol, or the same design with different patient populations i n 
each part.  
Period  A subdivision of a cross -over study  
Premature patient withdrawal  Point/time when the patient exits from the study prior to the planned completion of all investigational/ study treatment 
administration and all assessments (including follow -up) 
Randomization number  A unique identifier assigned to each randomized patient, 
corresponding to a specific treatment arm assignment  
Rebound  A subject experiences a rebound, if PASI increases to > 125% of 
baseline PASI, or if new pustular psoriasis, or new erythrodermic 
psoriasis, or more inflammatory psoriasis occurs within [ADDRESS_604595] dose of study treatment has been received.  
[COMPANY_001]  Confidential  Page 9 
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
Stop study participation  Point/time at which the patient came in for a final evaluation visit 
or when study/investigational  treatment  was discontinued 
whichever is later  
Study drug/ treatment  Any single drug  or combination of drugs administered to the 
patient as part of the required study procedures; includes investigational drug (s), active drug run- ins or background 
therapy  
Study/investigational treatment 
discontinuation  Point/time when patient permanently stops taking 
study/investigational treatment  for any reason; may or may not 
also be the point/time of premature patient withdrawal  
Variable  Inform ation used in the data analysis; derived directly or 
indirectly from data collected using specified assessments at 
specified time points  
[COMPANY_001]  Confidential  Page [ADDRESS_604596] marketing commitment be applied to this study: 
"Complete the treatment and evaluation of subjects enrolled in the ongoing CAIN457A2304E1 trial for a duration of 4 years, unless a safety signal is identified that indicates the potential risks of such continued long- term treatment outweigh the benefits. Evaluation of subjects should 
continue through the end of the trial when achievable (even if treatment is not continued for the duration). Subjects will be followed for the occurrence of serious infection, tuberculosis, opportunistic infections, malignancy, hypersensitivity reactions, autoimmune disease, 
neurologic or demyelinating disease, cardiovascular, gastrointestinal or hematologic adverse events".  
Subjects who complete treatment per iod and follow -up period are  evaluated for 4 years 
regarding respectiv e adverse events.  However, patient who prematurely discontinue treatment 
are evaluated for less than 4 years.  
Therefore, this amendment extends the evaluation of subjects who prematurely discontinue treatment regarding respective adverse events and concomitant medications in order to achieve 
a 4 year evaluation period . Evaluation of subjects should continue when achievable even if 
treatment is not continued for the duration. All subjects who prematurely discontinue treatment should complete all asses sment of Week 260 (end of treatment visit) and of the follow -up period 
visits (Weeks 264 and 268). Subsequently, adverse events and use of concomitant medication will be evaluated by [CONTACT_471720] [ADDRESS_604597] 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to implementation.  The changes herein affect the Informed Consent, and sites are required to update and submit for approval a revised Informed Consent that takes into account the changes described in this amended protocol. 
[COMPANY_001]  Confidential  Page 12  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
Amendme nt 1, 25- Apr-2014  
Amendment rationale  
The results of protocol CAIN457A2304 showed that the re -treatment at start of relapse 
maintenance regimen (SoR) was not non- inferior to a fixed interval regimen (FI) with treatment 
every four weeks and that patients e xperienced better maintenance of effect with secukinumab 
300 mg compared to secukinumab 150 mg; therefore, this amendment introduces an opportunity 
at week 156 for blinded subjects to 1) switch off of the SoR treatment regimen to treatment every four weeks  and 2) to increase the secukinumab dose to [ADDRESS_604598] one of these open label treatment option(s) depending on the current treatment assignment: 
 
Previous treatment arm through 
Week 152 (Unblinded at Week 
156) Treatment options, as decided by [CONTACT_471721] 156 
Secukinumab 300 mg FI  Continue  secukinumab 300 mg FI  Every 12 -16 weeks  
Secukinumab 300 mg SoR  Continue  secukinumab 300 mg SoR 
for remainder of the study  Every 4 weeks  
 OR Switch  to secukinumab 300 mg 
dosed every 4 weeks  Every 12- 16 weeks  
Secukinumab 150 mg FI  Continue  secukinumab 150 mg FI  Every 12 -16 weeks  
 OR Switch  to secukinumab 300 mg 
dosed every 4 weeks  Every 12- 16 weeks  
Secukinumab 150 mg SoR  Continue  secukinumab 150 mg SoR 
for remainder of the study  Every 4 weeks  
 OR Switch  to secukinumab 300 mg 
dosed every 4 weeks  Every 12- 16 weeks  
Additionally, this amendment extends the treatment duration for an additional 104 weeks (for 
a total of 5 years, one year in the core study or studies and four years in the extension study) and the opportunity for home administration of the study drug. In case secukinumab becomes 
commercially available in a participating country, the study might be discontinued in the respective country. This extension of treatment will allow for safety, tolerability, and efficacy data to be collected from the participating  subjects for up to a total of [ADDRESS_604599] on the primary objective of the trial. 
Changes to the protocol  
The main changes throughout the protocol introduce an opportunity for subjects to switch to 
treatment with open label secukinumab 300 mg s.c.  and to extend the treatment duration for an 
additional 104 weeks (two years) with the option for home administration in patients receiving secukinumab every four weeks. 
[COMPANY_001]  Confidential  Page 13  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
These specific changes were made to the protocol:  
• The length of the trial was changed from 2 to 4 years and visit names were updated as 
appropriate throughout the document: 
• Final treatment visit changed f rom Week 152 to Week 256 
• End of  Treatment period changed from Week 156 to Week 260 
• First Treatment- Free Follow -Up visit was changed from Week 160 to Week 264 
• End of Study changed from Week 164 to Week 268. 
• The synopsis was updated to reflect the changes in the main protocol text. 
• Section 3.[ADDRESS_604600] at home.   
• Figure [ADDRESS_604601] the new study design. 
• Section 3.[ADDRESS_604602] when combined with the core studies the trial will provide data on patients treated with secukinumab for five years.  
• Section 3.3 was updated with the primary conclusion of trial CAIN457A2304. 
• The risks and benefits of secukinumab were updated in Section 3.6 according to the increased experience and data reported in the Investigators Brochure Edition 13.   
• Section 3.[ADDRESS_604603] updated risk/benefit profile. 
• The section on treatment ( Section 5 ) was updated throughout to reflect the unblinding of 
patients at We ek [ADDRESS_604604] at home.  
Details of the treatment options are included in Section 5.2 and Table 5 -1. Table 5 -3 was 
added to summarize the overview of treatment and frequency of office visits between Week 156 and Week 256.  Details on instructions for home administrations are introduced in Section 5.5.4. 
• Section 5.5.8  and Table 5 -4 were updated to further clarify the use of prohibited 
concomitant treatment given the increased experience with the study drug.  
• Section 5.5.10, Section [IP_ADDRESS], and Section 6.6.[ADDRESS_604605] position Clinical Trial Head  
• Section 5.5.11 was updated to specify that in case secukinumab becomes commercially available in a participating country prior to all patients completing the study in that country, the study might be discontinued in the respective country.  
• Section 6  and Table 6 -1 were updated with assessments for Week 160 through Week 268 
• Section 9  was updated to include the secukinumab 300 mg open-label switch group for 
analysis  
• Section 9.4.[ADDRESS_604606] to endpoints. 
• Appendix 3 was updated with the increased duration of the study. 
Other minor corrections, clarifications, and editing changes of the protocol text were made in various sections 
[COMPANY_001]  Confidential  Page 14  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
Protocol synopsis  
 
Protocol number  CAIN457A2304E1 
Title A multicenter, double- blind and open label, 4 year extension study of 
subcutaneous secukinumab in prefilled syringes, assessing long- term 
safety, tolerability and efficacy in subjects with moderate to severe chronic 
plaque- type psoria sis treated with either a fixed dose regimen or on a 
retreatment at start of relapse regimen  
Brief title  
 4 year Extension Study of efficacy and safety of secukinumab in Patients with moderate to severe chronic plaque- type psoriasis   
Sponsor and Clinical  
Phase  [COMPANY_001]  
Phase 3  
Investigation type  Drug  
Study type  Interventional  
Purpose and rationale  To assess long- term safety and maintenance of efficacy in two different 
treatment regimens, a “fixed dose” regimen and a “retreatment at start of relapse” regimen.  
This four year (208 weeks), multicenter, double- blind and open label, 
extension study will collect long- term efficacy, safety and tolerability of 
secukinumab in the fixed dose and start of relapse treatment regimens.   
Primary Objective(s) and Ke y Secondary 
Objective Objective: To assess long- term safety and tolerability of secukinumab in 
subjects with moderate to severe chronic plaque- type psoriasis who 
completed treatment in the core studies CAIN457A2304 and 
CAIN457A2307.  
Secondary Objectives  
 • To evaluate the long- term efficacy of secukinumab administered 
at the start of relapse versus fixed interval regimens, in subjects with moderate to severe chronic plaque- type psoriasis who are 
PASI [ADDRESS_604607] to PASI 75 response:  
• at Weeks 104 and 156, for subjects in the fixed interval 
regimens, or  
• at Weeks 92 and 144, for subjects in the retreatment at start 
of relapse regimen who do not require active treatment at Week 92 or 144, respectively, or  
• at Weeks 104 and 156, for subjects in the retreatment at start of relapse regimen who do require active treatment at Week 92 or 144, respectively.  
• To evaluate the efficacy of secukinumab treatment regimens in subjects with moderate to severe chronic plaque- type psoriasis 
with respect to PASI 50/75/90/100 and IGA 0 or 1 response over time.   
• To evaluate the effects of treatment regimens with secukinumab 
in subjects with moderate to severe chronic plaque type psoriasis 
with respect to PASI score and IGA mod2011 score over time  
• To assess the effects of secukinumab treatment regimens with 
respect to EQ -5D score over time  
[COMPANY_001]  Confidential  Page 15  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
• To investigate the effects of treatment regimens with 
secukinumab in subjects with moderate to severe chronic plaque-type psoriasis with respect to changes in DLQI over time 
• To investigate the effects of treatment regimens with secukinumab in subjects with moderate to severe chronic plaque-type psoriasis with respect to DLQI 0 or 1 achievement over time 
• To investigate the potential development of immunogenicity 
against se cukinumab  
Study design  This is a multicenter, double- blind and open label, trial in subjects with 
moderate to severe chronic plaque- type psoriasis who completed treatment 
in the maintenance period of studies CAIN457A2304 or CAIN457A2307. 
This extension study consists of three to four periods: the screening period, 
the treatment period, the treatment - free follow -up period (for all subjects) , 
and the follow -up 2 period (only for subject who prematurely discontinued 
treatment) . 
Population  All subjects who complete treatment in the maintenance period of studies 
CAIN457A2304 or CAIN457A2307 and meeting inclusion & exclusion 
criteria are eligible for this study. Approximately [ADDRESS_604608] to fulfill all of the following criteria:  
• Subjects must be able to understand and communicate with the investigator and comply with the  requirements of the study and 
must give a written, signed and dated informed consent before any study related activity is performed.  Where relevant, a legal representative will also sign the informed consent according to local laws and regulations.  
• Subjects who complete Week 52 of study CAIN457A2304 or complete Week 40 of study CAIN457A2307  
• Subjects expected to benefit from participation in the extension 
study, as assessed by [CONTACT_471722]:  
• A protocol deviation in the core studies which according to the 
investigator will prevent the meaningful analysis of the extension 
study for the individual subject  
• Ongoing use of prohibited psoriasis or non- psoriasis treatments. 
Time period from last use of prohibited treatments in the core study to first dose of study drug in this extension study detailed in Table 5-[ADDRESS_604609] be adhered to.  
• Subjects expected to be exposed to an undue safety risk if participating in the trial  
• Current severe progressive or uncontrolled disease which in the judgment of the investigator renders the subject unsuitable for the trial 
• Plans for administration of live vaccines during the study period  
• Pregnant or nursing (lactating) women, where pregnancy is 
defined as the state of a female after conception and until the 
[COMPANY_001]  Confidential  Page [ADDRESS_604610] (>10 mIU/mL).  
• Women of child- bearing potential, defined as all women 
physiologically capable of becoming pregnant, unwilling to use 
effective contraception during the study and for a minimum of 16 
weeks after stoppi[INVESTIGATOR_056].  
Investigational and reference therapy Secukinumab Prefilled Syringes for s.c. administration  
Placebo Secukinumab Prefilled Syringes for s.c. administration  
Efficacy assessments  Investigator’s Global Assessment (IGA mod 2011; scale from 0 – 4) 
Psoriasis Area and Severity Index (PASI; score from 0 – 72) 
Rebound assessment  
Safety assessments  Evaluation of all AEs and SAEs including injection site reactions  
Physical examination  
Vital signs  
Laboratory evaluations  
Hematology  
Clinical chemistry  
Urinalysis  
Immunogenicity (assessment of anti- secukinumab antibody development)  
Electrocardiogram  
Pregnancy and assessments of fertility  
Other assessments  Fasting laboratory evaluations,  
Health- related quality of life assessments such as  
DLQI  
EQ-5D 
HAQ -DI (only in subjects with psoriatic arthritis from study CAIN457A2304, 
not CAIN457A2307)  
PK assessments  
Data analysis  Treatment groups for analysis will include:  
Secukinumab 150 mg fixed interval  
Secukinumab 300 mg fixed interval  
Secukinumab 150 mg start of relapse  
Secukinumab 300 mg start of relapse  
Secukinumab 300 mg open -label  
Secukinumab 300 mg open -label switch  
The primary analysis will focus on safety variables. All safety evaluations will be performed on the Safety set (all subjects who took at least one dose 
of study treatment during the treatment period.)  
[COMPANY_001]  Confidential  Page 17  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
Maintenance of response will be defined analogously a s in the primary 
endpoint in CAIN457A2304, but for week 104 and 156, i.e. PASI 75 
response  
at Weeks 104 and 156, for subjects in the fixed interval regimens, or  
at Weeks 92 and 144, for subjects in the retreatment at start of relapse 
regimen who do not req uire active treatment at Week 92 or 144, 
respectively, or  
at Weeks 104 and 156, for subjects in the retreatment at start of relapse 
regimen who do require active treatment at Week 92 or 144, respectively.  
Key words  4 year Extension Study, in Patients with moderate to severe chronic plaque 
type psoriasis  
 
[COMPANY_001]  Confidential  Page 18  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
1 Introduction  
1.1 Background  
CAIN457A2304E1 is an extension study to two phase III studies, CAIN457A2304 and 
CAIN457A2307 (core studies).  Study CAIN457A2304 compares the maintenance of efficacy and safety o ver time in two different treatment regimens: a fixed dose regimen and a retreatment 
at start of relapse regimen.  Efficacy is measured with PASI response rates; a PASI 75 is defined 
as a responder whereas a PASI 50 to less than PASI 75 is a partial responder.  In study 
CAIN457A2304, PASI 75 responders at Week 12 continued to the end of the study but partial responders were offered either participation in study CAIN457A2307 or entering the treatment -
free follow -up period in CAIN457A2304. Study CAIN457A2304 non-responders at week 12 
(PASI response less than 50) were discontinued from treatment and entered the treatment -free 
follow-up period in CAIN457A2304. 
Study CAIN457A2307 evaluates whether a partial responder can be converted to a responder 
when treated f or longer periods of time and/or when treated with a higher dose of the drug via 
either the s.c. or the i.v. route of administration. Please refer to the protocols of the core studies for full details.  
This extension study is planned to collect up to four years of long- term safety, tolerability and 
efficacy data of secukinumab in both the fixed interval regimen and the retreatment at start of relapse regimen. All subjects completing Week 52 of CAIN457A2304 and Week 40 of CAIN457A2307 will be eligible to participate in this extension study. Week 40 of the CAIN457A2307 study is the end of maintenance visit (EOM) and is equivalent to the Week 52 (EOM) of the CAIN457A2304 core study. Therefore, all subjects entering the CAIN457A2304E1 study will have received 52  weeks of treatment in their previous study / 
studies.   The Week 52 (CAIN457A2304) and Week 40 (CAIN457A2307) of the two core studies will together be referred to as “the EOM visit” (end of maintenance visit for the core studies) in this protocol. 
In this  extension study, the prefilled syringe (PFS) liquid formulation of secukinumab will be 
used. This study may be affected by [CONTACT_471723], 
whereby [CONTACT_471724] (via a future protocol amendment) based on eventual agency recommendations for product usage in this indication. 
1.2 Purpose  
The purpose of this extension study is to assess long -term safety and maintenance of effi cacy 
in two different treatment regimens, a “fixed dose” regimen and a “retreatment at start of relapse” regimen.  Within each regimen, two different doses are used: 150 and 300 mg s.c. secukinumab.  A successful response is defined as a PASI 75, and subje cts who meet this 
criterion are referred to as “responders”.   A PASI [ADDRESS_604611] achieving ≥ 75% improvement (reduction) in PASI score compared to baseline of the core study.   
[COMPANY_001]  Confidential  Page 19  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
Subjects who complete the extension study will provide up to approximately 4 years of 
additional data to the CAIN457A2304 and CAIN457A2307 core studies, which will be submitted as supplemental information to support the appropriate individualized use of secukinumab for the treatment of moderate to severe, chronic, plaque-type psoriasis.   
Subjects who finished the treatment period in studies CAIN457A2304 or CAIN457A2307 and 
show a meaningful response (as assessed by [CONTACT_136713]) will be enrolled into this extension study to allow them to continue treatment with secukinumab, which will not yet be commercially available at the time of enrollment.  
2 Study objectives  
2.1 Primary and key secondary objectives  
To assess long -term safety and tolerability of secukinumab in subjects with moderate to severe 
chronic plaqu e-type psoriasis who completed treatment in the core studies CAIN457A2304 and 
CAIN457A2307. 
2.2 Secondary objectives  
• To evaluate the long -term efficacy of [ADDRESS_604612] to PASI 75 response: 
• at Weeks 104 and 156, for subjects in the fixed interval regimens, or 
• at Weeks 92 and 144, for subjects in the retreatment at start of relapse regimen who do not require active treatment at Week 92 or 144, respectively, or 
• at Weeks 104 and 156, for subjects in the retreatment at start of relapse regimen who 
do require active treatment at Week 92 or 144, respectively. 
• To evaluate the efficacy of secukinumab treatment regimens in subjects with moderate to 
severe chronic plaque -type psoriasis with respect to PASI 50/75/90/100 and IGA 0 or 1 
response over time.   
• To evaluate the effects of treatment regimens with secukinumab in subjects with moderate to severe chronic plaque type psoriasis with respect to PASI score and IGA mod 2011 score over time  
• To assess the effects of secukinumab treatment regimens with respect to EQ -5D score over 
time 
• To investigate the effects of treatment regimens with secukinumab in subjects with moderate to severe chronic plaque- type psoriasis with respect to changes in DLQI over time  
• To investigate the effects of treatment regimens with secukinumab in subjects with moderate to severe chronic plaque- type psoriasis with respect to DLQI 0 or 1 achievement 
over time  
[COMPANY_001]  Confidential  Page 20  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
• To investigate the potential development of immunogenicity against secukinumab 
• To investigate the occurrence of relapses (achieved maximal PASI i mprovement from 
baseline in core study is reduced by >50%) and rebounds in subjects on secukinumab 
therapy  
2.3 Exploratory objectives 
•  
• To explore the effects of secukinumab with respect to the HAQ- DI in subjects from core 
study CAIN457A2304 with psoriatic arthritis (PsA) at baseline over time  
•   
3 Investigational plan 
3.1 Study design 
This is a multicenter, double -blind and open label, trial in subjects with moderate to severe 
chronic plaque -type psoriasis who completed treatment in the maintenance period of studies 
CAIN457A2304 or CAIN457A2307. It was expected that approximately 740 subjects would be enrolled at approximately 130 study sites worldwide. When recruitment was complete, 675 subjects had been enrolled at 112 sites.    
This extension study consists of four periods: the screening period, the treatment period, and 
two follow -up periods (follow -up and follow up 2). An outline of the visits is presented in 
Figure 3 -1, while a detailed visit schedule can be found in Table 6 -1. 
Screening Period 
The screening period for the extended maintenance portion of the study is the duration between 
the signing of the informed consent form and enrollment registered with the interactive response technology (IRT).  There are no additional requirements for the  treatment period other than subjects are required to complete year 1 of the core studies and all assessments at the end of maintenance visit (Week 52) of core study CAIN457A2304 or end of maintenance visit (Week 40) of core study  CAIN457A2307.  Subjects who complete the EOM visit and assessments of the core studies and consent to the extension will continue directly into the treatment period of this extension study. Subjects must sign the informed consent form (ICF) for the treatment period once the core assessments have been complet ed for Week [ADDRESS_604613] completed the core study (CAIN457A2304 or CAIN457A2307).  For the purpose of reading and understanding, the ICF can be provided to subjects anytime during the core studies, for example, between Week 48 and prior to the dose at Week 52 of study CAIN457A2304 (Weeks 36 and 40 from study CAIN457A2307 are equivalent to Weeks 48 and 52 of CAIN457A2304).  However, subjects will NOT sign the ICF before completing the core studies’ EO M assessments.  

[COMPANY_001]  Confidential  Page 21  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
Note: subjects from CAIN457A2307 started their visits in that study after completing 12 Weeks 
of the CAIN457A2304 core study; therefore, Week 40 of the CAIN457A2307 study is equivalent to Week 52 of the CAIN457A2304 and CAIN457A2304E1 studie s as regards 
previous treatment duration (i.e., 52 weeks). 
The dose administered at Week [ADDRESS_604614] dose of the CAIN457A2304E1 treatment period.   
Treatment Period  
The treatment period is defined as Weeks 52 through 260.   
Subjects from the CAIN457A2304 maintenance period will continue the treatment regimen and 
dose that they were assigned to (Fixed interval regimen or Retreatment at start of relapse regimen) during the maintenance treatment period of the core study and return for visits every four wee ks up until Week 156.  Subjects and study personnel will remain blinded during the 
first two years of the treatment period (except for patients in the open label part of the study).  The last blinded dose of the treatment period is administered at Week 152.   
At Week 156, subjects will be unblinded and will have the option (based on investigator 
judgment) to switch dosing regimens, with the specific options depending on the blinded treatment assigned until that point.  Generally, subjects may switch off of the SoR treatment 
regimen to active secukinumab treatment every four weeks, and subjects may switch from secukinumab 150 mg s.c. to secukinumab 300 mg s.c.  After Week 156, office visits will only be required every 12 -16 weeks until Week 260 (End of Treatment period for 
CAIN457A2304E1) unless a subject continues with the SoR treatment regimen.  Specific details of the open- label treatment options for unblinded subjects starting at Week 156 are 
described in Section 5.2 and in Table 5-1.   
Subjects from the CAIN457A2307 maintenance period will continue in the treatment regimen 
and dose that they received during the CAIN457A2307 maintenance treatment period (i.e.,  300 mg sc secukinumab every four weeks), and return for visits every four weeks up until Week 156.  After Week 156, subjects will continue being treated every four weeks, but will only be required to come in for office visits every [ADDRESS_604615] 
all Week 260 protocol assessments (EOT) performed approximately four weeks after their last dose of secukinumab/secukinumab placebo and then enter t he treatment -free follow -up periods 
(follow -up period and follow-up 2 period). 
Follow -up period (for all subjects)  
Subjects who complete the treatment period (the end of the treatment phase visit is at Week 
260) will enter the treatment free follow -up period with the following visits: Week 264 (Follow -
up visit 4, F4), which is [ADDRESS_604616] dose), and Week 268 (Follow -up visit 8, F8 or End of Follow -up, EOF) which is [ADDRESS_604617] dose). Subjects who prematurely discontinue treatment 
should complete all assessment of Week 260 (end of treatment visit) and then enter follow -up 
period with Weeks 264 and 268 visits. 
Subjects within the follow -up period who withdraw from study should  perform Week 268 
assessments (EOF).  
Follow -up 2 period (only for subjects who prematurely discontinued treatment)  
Subjects who have prematurely discontinued treatment prior to the  end of treatment phase 
(Week 260), and completed the Week 260 visit and the subsequent follow -up period visits 
(Weeks 264 and 268) should enter the treatment -free follow -up 2 period. Follow -up 2 period 
consists of telephone calls every 3 months and unplanned assessments e.g. unscheduled 
physical examinations, vital sig ns and laboratory assessments at the site if investigator considers 
this necessary. The end of Follow -up 2 period (EOF2) for an individual subject will be after [ADDRESS_604618] has been enrolled into the CAIN457A2304E1 study (Figure 3.1). 
Subjects within the follow -up 2 period who withdraw from study will be recorded in the End of 
Follow-up 2 (EOF2) completion eCRF page.  
[COMPANY_001]  Confidential  Page 23  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
Figure 3-1 Study design 
 
 
3.2 Rationale of study design 
This four year (208 weeks), multicenter, double -blind and open label, extension study will 
collect long -term efficacy, safety and tolerability of secukinumab in the fixed dose and start of 
relapse treatment regimens.  The randomization to the treatment arms occurred in the core 
studies and is carried over into this extension study. 
The total study duration of four years will allow for assessment of long term safety and efficacy 
in subjects treated for up to five years when combined with data from the core studies. The 
regular assessments of disease activity and clinical status ensure that safety is monitored closely, and that both subject and investigator have the opportunity to assess if the continued 

[COMPANY_001]  Confidential  Page [ADDRESS_604619]’s benefit. If the subject’s participation 
is deemed not to be of benefit to the subject, the subject can discontinue study treatment at any 
time.  
Subjects who complete the extension study will provide up to approximately 4 additional years of long-term safety, tolerability and efficacy data, to the CAIN457A2304 core study.  
Subjects who finished the treatment period in studies CAIN457A2304 or CAIN457A2307 and 
show a meaningful response (as assessed by [CONTACT_471725]) will be enrolled into 
this extension study to allow them to continue treatment with secukinumab, which is not yet commercially available at the time of enrollment.  
3.3 Rationale of dose/regimen, route of administration and duration 
of treatment 
The doses and regimens selected for the secukinumab phase III program were based on phase II trial data.   As of the trial initiation, there has not been any data to date to indicate that the doses used in the core studies should be modified.  Therefore, this extension study will continue treatment with secukinumab s.c. doses of 150 mg and 300 mg administered every four weeks, and/or at start of relapse (following the randomization that was done during the core studies) for an additional 208 weeks.  This will provide long- term secukinumab efficacy and safety data 
pertaining to the treatment of subjects suffering from chronic plaque -type psoriasis for up to a 
total of 5 years when combined with the core studies data. 
The pi[INVESTIGATOR_471708]457A2304 showed that the re- treatment at start of relapse maintenance regimen 
(SoR) was not non- inferior to a fixed interval regimen (FI) with treatment every four weeks and 
subjects experience bette r efficacy with 300 mg secukinumab s.c. every four weeks compared 
to 150 mg secukinumab s.c. every four weeks with similar safety profile between the two doses. 
Therefore, at Week 156 all patients treated with the SoR treatment regimen are given the option  
to switch to treatment with active secukinumab every four weeks, and patients treated with secukinumab 150 mg s.c. are given the option to switch to treatment with secukinumab 300 mg s.c.  Any switches in treatment regimen or dose are to be made according  to the investigator’s 
judgment as the investigator will have three years of experience with the subject and the subject’s individual response to secukinumab.    
The switch from the lyophilisate to the more convenient prefilled syringe (PFS) is supported b y 
the results of the clinical study CAIN457A2106, which has shown that the exposure and safety 
profiles of both formulations are highly comparable. 
3.4 Rationale for choice of comparator 
This extension study uses the same treatments that were assigned during the core CAIN457A2304 and CAIN457A2307 studies.  Therefore, no comparators are used. 
3.5 Purpose and timing of interim analyses/design adaptations 
One interim analysis is planned for this study.  At time of marketing authorization submission of the AIN457A project, the safety data of this extension study will be reported. Since the core studies have been unblinded at that stage, this interim analysis will also be unblinded. Of note, 
[COMPANY_001]  Confidential  Page 25  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
investigators, subjects and site staff will remain blinded to individual treatme nt group 
assignments.  
Further interim analyses, as regarded appropriate, might be conducted (e.g., to provide 
additional data for regulatory or publication purposes). 
When each subject in the study has either completed treatment period and follow-up period, or  
discontinued treatment and completed follow -up and follow -up 2 periods  (last telephone 
contact), or withdrawn from study, the final database lock occurs.  
3.[ADDRESS_604620] not shown any impediment to using secukinumab administered 
subcutaneously in man.  Study CAIN457A2304E1 will use secukinumab drug substance solution in a PFS formulation; biocomparability of secukinumab in PFS and lyophilized formulations has been demonstrated (study CAIN457A2106), with highly comparabl e 
pharmacokinetic properties.  
At the time of Amendment 1, over [ADDRESS_604621] received secukinumab.  Details of the risk and benefits are outlined in the current version of the Investigator Brochure. 
The risk to subjects in this trial will be minimized by [CONTACT_374632]/exclusion 
criteria, proper study design, and close clinical monitoring. 
In this extension study, CAIN457A2304E1, all subjects will receive active treatment, either 
every four weeks regardless of clinical symptoms, or after they have experienced start of  relapse. To ensure a double -blind design, some subjects will receive placebo at certain visits, 
according to their treatment group.  For example, patients in the core study CAIN457A2304  
who were randomized to and continue on the retreatment at start of relapse regimen who have not experienced a start of relapse will continue on placebo medication until they meet the start of relapse criteria.  
All quality, non -clinical pharmacology and to xicology data, as well as the available clinical 
efficacy and safety data, are considered sufficient to expect a positive benefit / risk ratio for the treatment of psoriasis with secukinumab, and therefore to initiate this extension study CAIN457A2304E1. 
[ADDRESS_604622] of a representative group of male and female outpatients (≥ 18 years old) with moderate to severe chronic plaque -type psoriasis who completed the full 
study treatment period (52 weeks) in the core studies CAIN457A2304 or CAIN457A2307 (Week 40 in study CAIN457A2307 is equivalent to a total of 52 weeks of treatment with secukinumab). 
Study CAIN457A2304 randomized 970 subjects. Assuming that 5% of the subjects drop -out 
up to Week 12, and further 15% drop- out in CAIN457A2304 or CAIN457A2307 it is estimated 
that about [ADDRESS_604623] to fulfill all of the following criteria:  
1. Subjects must be able to understand and communicate with the investigator and comply 
with the requirements of the study and must give a written, signed and dated informed consent before any study related activity is performed.  Where relevant, a legal 
representative will also sign the informed consent according to local laws and regulations. 
2. Subjects who complete Week [ADDRESS_604624] and investigator 
4.2 Exclusion criteria 
Subjects fulfilling any of the following criteria are NOT  eligible for inclusion in this study:  
1. A protocol deviation in the core studies which according to the investigator will prevent the meaningful analysis of the extension study for the individual subject 
2. Ongoing use of prohibited psoriasis or non- psoriasis treatments. Time period from last use 
of prohibited treatments in the core study to first dose of study drug in this extension study detailed in Table [ADDRESS_604625] unsuitable for the trial 
5. Plans for administration of live vaccines during the study period 
6. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>10 mIU/mL). 
7. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unwilling to use effective contraception during the study and for 16 weeks after stoppi[INVESTIGATOR_056]. Effective contraception is defined as either: 
• Barrier method: Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicide (where available). Spermicides alone are not a barrier m ethod of 
contraception and should not be used alone  
The following methods are considered more effective than the barrier method and are also 
acceptable:  
• Total abstinence: When this is in line with the preferred and usual lifestyle of the subject (Periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception) 
• Female sterilization: have had a surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_471726] 27  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
• Male partner sterilization (at least 6 months prior to screening). For female 
subjects on the study, the vasectomised male partner should be the sole partner for that subject  
• Use of established oral, injected or implanted hormonal methods of contraception, intrauterine device (IUD) or intrauterine system (IUS) 
NOTE: Women are considered post-menopausal and not of child bearing potential if they 
have had: 
• 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or  
• six months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL [for US only: and estradiol <20 pg/mL] or 
• surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_6592]. 
No additional exclusion criteria may be applied by [CONTACT_093], in order to ensure that the study population will be representative of all eligible subjects.  
[ADDRESS_604626] the option to switch to treatment with active secukinumab every four weeks, and subjects treated with secukinumab 150 mg s.c. are given the option to switch to treatment with secukinumab 300 mg s.c.  Details of these switch options are provided in 
Section 5.2. 
Subjects from CAIN457A2307 are treated open label and will continue to receive the same 
treatment (300 mg s.c. every four weeks) in the CAIN457A2304E1 extension study. 
All of the packaging for the treatments in this study will be packaged to maintain the blind.  
There will not be any syringes or boxes labeled in an open- label manner as the IRT will be 
responsible for assigning the appropriate medication numbers to each subject.  Although the labels on the treatments will not indicate active, the investigator and subjects from the CAIN457A2307 core study will know that the content of the PFSs that are assigned to these subjects during the CAIN457A2304E1 study  are active since the subjects will receive the same 
treatment that they were assigned to during the maintenance period of the core studies.  Also, after Week 156, although the labels on the treatment assigned to the subjects from the CAIN457A2304 will not  indicate active or placebo treatment, the investigator and subjects will 
know what they are being treated with due to the unblinding at Week 156. 
[COMPANY_001]  Confidential  Page 28  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
5.1 Protocol requested treatment  
5.1.1  Investigational treatment  
[COMPANY_001] will supply the following study treatment: 
1. Investigational treatment: Secukinumab 150 mg/1 mL solution for injection is 
provided in PFS for s.c. administration. The 150 mg/1 mL solution in PFS is used for 
both the s.c.150 mg dose (1 syringe) and s.c. 300 mg dose (2 syringes). For blinding purposes the subjects in the 150 mg treatment group will also receive one syringe of placebo 150 mg. 
2. Placebo secukinumab 150 mg/1 mL solution for injection is provided in PFS for s.c. administration. It contains a mixture of inactive excipi[INVESTIGATOR_840], matching the composition of secukinumab 150 mg. 
Secukinumab 150 mg/1 mL and placebo secukinumab 150 mg/1 mL is labeled as AIN457 150 mg/1 mL/Placebo.  
5.1.2  Additional study treatment  
No additional treatment beyond investigational treatment is requested for this trial.  
5.2 Treatment arms 
Subjects will continue in the treatment arm that they were assigned to during the CAIN457A2304 core study or the CAIN457A2307 core study until Week 156.  At Week 156, subjects who rolled over from the CAIN457A2304 core study will be unblinded and may swit ch 
to one of the treatment options described below according to investigator judgment; subjects who rolled over from the CAIN457A2307 core study will continue being treated with secukinumab [ADDRESS_604627], dose groups in this proposed extension trial may be amended (via a future protocol amendment) based on eventual agency recommendations for product usage in this indication. 
The study treatment will be provided in individual boxes that contain secukinumab or placebo 
PFS sealed in a plastic wrapper.  Each study treatment box consists of actual PFS and a safety device type X100L .  The safety syringe is provided with a needle guard 
system that will aid protection from accidental needle sticks.  
Double -blind treatment arms for subjects entering from the CAIN457A2304 core 
study  
During the core study CAIN457A2304, wi thin each treatment regimen, subjects were assigned 
to either the 150 or 300 mg s.c. secukinumab in PFS, thus resulting in four treatment arms overall which will be maintained until Week 156: 
Fixed -time interval regimen – “FI”: either 150 or 300 mg s.c. secukinumab in PFS:  In the 
treatment period subjects will receive the same dose they received during the maintenance 
period of the CAIN457A2304 core study. Thus, secukinumab 150 mg subjects will continue to 

[COMPANY_001]  Confidential  Page 29  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
receive 150 mg secukinumab every four weeks, and secukinumab 300 mg subjects will continue 
to receive 300 mg secukinumab every four weeks, from Week 52 up to and including Week 152. 
Retreatment at start of relapse regimen – “SoR” “start of relapse”: either 150 or 300 mg s.c. 
secukinumab in PFS: “Start of relapse” will be defined as a loss of ≥20% of the maximum PASI 
gain achieved during the CAIN457A2304 or CAIN457A2304E1 study, compared to baseline 
of the CAIN457A2304 study, and a loss of PASI  [ADDRESS_604628] fulfills the 
start of relapse criteria, active secukinumab will be administered at their scheduled visits (i.e., 
every four weeks) until the subject is back to PASI 75 response, at which point in time they will start receiving placebo again. The dose administered in the treatment perio d of this extension 
study (secukinumab 150 mg or 300 mg in PFS) will be identical to the dose that these subjects received during the maintenance period of the CAIN457A2304 core study. If a subject does not fulfill the criteria of a start of relapse or is back to PASI 75 response after a start of relapse, they 
will receive placebo PFS injections (two injections per dose) to maintain the blind. This treatment regimen is applied every four weeks, from Week 52 up to and including Week 152. 
At Week 156, patients from the maintenance period of the CAIN457A2304 core study will be 
unblinded and continue in the study on one of the treatment options in Table 5 -1 according to 
investigator judgment for their assigned treatment arm.  
Table 5-1 Open- label treatment options starting at Week 156  
Previous treatment arm through 
Week 152 (Unblinded at Week 
156) Treatment options, as decided by [CONTACT_471727] 300 mg FI  Continue  secukinumab 300 mg FI  Every 12 -16 weeks  
Secukinumab 300 mg SoR  Continue  secukinumab 300 mg SoR 
for remainder of the study  Every 4 weeks  
 OR Switch  to secukinumab 300 mg 
dosed every 4 weeks  Every 12- 16 weeks  
Secukinumab 150 mg FI  Continue  secukinumab 150 mg FI  Every 12 -16  weeks  
 OR Switch  to secukinumab 300 mg 
dosed every 4 weeks  Every 12- 16  weeks  
Secukinumab 150 mg SoR  Continue  secukinumab 150 mg SoR 
for remainder of the study  Every 4 weeks  
 OR Switch  to secukinumab 300 mg 
dosed every 4 weeks  Every 12- 16  weeks  
Open- label treatment arm for subjects entering from the CAIN457A2307 core 
study  
Secukinumab 300 mg s.c. in PFS regimen arm: Each subject to continue receiving two s.c. 
injections of 150 mg secukinumab in PFS every four weeks.  Doses will be administered from 
Week 52 up to and including Week 256. 
[COMPANY_001]  Confidential  Page 30  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
Overview of treatment schedule according to treatment arm  
The treatment details for each treatment arm for Week 52 through Week 152 are highlighted in 
Table 5 -2 below.  The treatment details for each treatment assignment for Week 156 through 
Week 256 are highlighted in Table 5 -3 below. 
Table 5-2 Overview of treatment between Week 52 and Week 152  
Treatment arm  Double -blinded A2304 subjects:  
 Week 52  to   Week 152   Open -label A2307 subjects:  
Week 52  to  Week 152  
secukinumab 150 
mg fixed interval  1 s.c. secukinumab 150 mg PFS 
injection +  
1 s.c. PBO secukinumab PFS 
injection  N/A 
secukinumab 300 
mg fixed interval  2 s.c. secukinumab 150 mg PFS 
injections  2 s.c. secukinumab 150 mg PFS 
injections  
secukinumab 150 mg at start of relapse  At start of relapse and until PASI 75 is 
regained : 
1 s.c. secukinumab 150 mg PFS injection +  
1 s.c. PBO secukinumab PFS 
injection  N/A 
Otherwise:  
2 s.c. PBO secukinumab PFS 
injections  N/A 
secukinumab 300 
mg at start of 
relapse  At start of relapse and until PASI 75 is 
regained : 
2 s.c. secukinumab 150 mg PFS 
injections  N/A 
Otherwise:  
2 s.c. PBO secukinumab PFS 
injections  N/A 
PBO = placebo; PFS=pre- filled syringe  
Table 5-3 Overview of treatment between Week 156 and Week 256  
Assigned treatment  Treatment delivered and frequency of office visits  
secukinumab 150 mg fixed interval  1 s.c. secukinumab 150 mg PFS injection every four weeks  
Office visits required every 12 -16 weeks  
secukinumab 300 mg fixed interval/ 
every four weeks  2 s.c. secukinumab 150 mg PFS injections every four weeks  
Office visits  required every 12 -16 weeks  
secukinumab 150 mg at start of relapse  1 s.c. secukinumab 150 mg PFS injection every four weeks 
upon meeting SoR criteria and until PASI 75 is regained; no treatment otherwise  
Office visits required every 4 weeks  
secukinumab 300 mg at start of 
relapse  2 s.c. secukinumab 150 mg PFS injection every four weeks upon meeting SoR criteria and until PASI 75 is regained  
No treatment otherwise  
[COMPANY_001]  Confidential  Page 31  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
Assigned treatment  Treatment delivered and frequency of office visits  
Office visits required every 4 weeks  
5.3 Treatment assignment 
Patients will continue receiving study treatment as per their treatment arm in the core studies 
(i.e., CAIN457A2304 or CAIN457A2307) until Week 156. The randomization numbers will be generated using the following procedure to ensure that treatment assignment is concealed from patients and investigator staff. A randomization list will be produced by [CONTACT_90181] a validated system that automates the random assignment of treatment arms to randomization numbers in the specified ratio.  
At the end of Week 52 of CAIN457A2304 (or Week 40 of CAIN457A2307), the investigator 
will complete core study assessments, enter the PASI response into the eCRF and register the 
completion of core study visit in the IRT. The Week 52 of CAIN457A2304 (or Week 40 of CAIN457A2307) visit in the core study is the randomization visit for CAIN457A2304E1. Based on the fulfillment of inclusion/exclusion criteria by [CONTACT_471728] 52 (explained above), the investigator (or designee) will call the IRT set up of CAIN457A2304E1. The randomization number will be adopted from core study (CAIN457A2304 and CAIN457A2307) in this extension study and IRT will only specify a unique medication number for the first package of investigational treatment to be dispensed to the patient. The randomization number will not be communicated to the caller and the treatment assignment will be unbiased and concealed from patients and investigator staff.  
The randomization list from the co re study CAIN457A2304 or CAIN457A2307 will be adopted 
for this extension study. A separate medication list will be produced by [CONTACT_90181] a validated system that automates 
the random assignment of medication numbers to packs containing the investigational drug(s). 
At Week 156, all subjects will be unblinded and will continue with one of the treatment options 
described in Section 5.2 based on their previous treatment arm and the investigator’s judgment.  
The investigator should select the best option from the options based on the assigned treatment up to that point.  This selection should be based on knowledge of and experience with the patient.  
5.4 Treatment blinding 
Subjects, investigator staff and persons performing the assessments will remain blind to the identity of the treatment, for subjects who participated in the core CAIN457A2304 study, from the time of enrollment in the extension study until Week 156, using the following methods:  
(1) Randomization data from the core study are kept strictly confidential until the time of 
unblinding, and will not be accessible by [CONTACT_121927]  
(2) The identity of the treatments will be concealed by [CONTACT_471729], schedule of administration and appearance. Unblinding will only occur in the case of subject emergencies (see Section 5.5.11).  
In order to maintain the blind for the subjects coming from study CAIN457A2304, placebo PFSs are used.  
[COMPANY_001]  Confidential  Page [ADDRESS_604629] Number is maintained from the core study/ studies in the extension. 
Upon signing the informed consent form, the investigator or his/her staff will contact [CONTACT_471730]. The site should select the CRF book with a matching Subject Number from the EDC system to enter data.  
If the patient fails to be treated for any reason, the IRT must be notified within two  days that 
the patient was not treated. The reason for not being treated will be entered on the Screening Epoch Study Disposition CRF. 
5.5.2  Dispensing the investigational treatment  
Each study site will be supplied by [CONTACT_471731] p ackaging of 
identical appearance.  
The investigational treatment packaging has a two -part label. A unique randomization number 
is printed on each part of this label which corresponds to one of the 5 treatment arms and a 
specific visit. Investigator staff will identify the investigational treatment package(s) to dispense to the patient by [CONTACT_105245](s). Immediately before dispensing the package to the patient, investigator staff will detach the outer part of the label from the packaging and affix it to the source document (Drug Label Form) for that 
patient’s unique subject number.  
5.5.3  Handling of study treatment  
[IP_ADDRESS]  Handling of investigational treatment  
Investigational treatment must be received by a designated person at the study site, handled and 
stored safely and properly, and kept in a secured location to which only the investigator and designees have access. Upon receipt, all investigational treatment should be stored according to the instructions specified on the labels. Clinical supplies are to be dispensed only in accordance with the protocol. 
Medication labels will be in the local language and comply with the legal requirements of each 
country. They will include storage conditions for the investigational treatment but no 
[COMPANY_001]  Confidential  Page [ADDRESS_604630] will 
require two boxes of PFSs per dose. 
• One secukinumab 150 mg PFS and one placebo secukinumab PFS (150 mg dose) OR  
• Two secukinumab 150 mg PFS (300 mg dose) OR   
• Two placebo secukinumab 150 mg PFS (Placebo dose for subjects in the SoR regimen, who have not relapsed)  
After Week 156, subjects with site visits every 12- 16 weeks will be expected to perform home 
administrations at the protocol specified time points (ev ery 4 weeks) when there is no correlated 
office visit.  In these cases, the investigator will dispense, via IRT, the appropriate number of investigational treatment packages for the planned home administrations until the next expected site visit and detach  the outer part of the label from the packaging prior to giving the package 
to the subject.  The subjects will record the date(s) of administration at home and will return the used medication and packaging at their next site visit.  Subjects will be asked to return all unused 
medication and packaging at the latest by [CONTACT_471732].  Site staff will record the dates of administration on the appropriate documents.   
All study treatment kits assigne d to the subject during the study will be recorded / databased in 
the IRT.  
The syringes with the ready -to-use study treatment solution (PFS) will be provided by [CONTACT_471733].  
The first study treatment administration will occur at W eek 52 (enrollment into the extension) 
after all study scheduled assessments have been performed (and inclusion / exclusion criteria 
confirmed) and only after the scheduled blood samples have been drawn.  It is preferred that the subject self -inject the tr eatment during the site visit, however, if a subject is not able or not 
willing to self -administer, administration will be performed by [CONTACT_108575].  If the subject is 
not able or not willing to self -administer the PFS at home, he/she may come into th e site for 
dosing every [ADDRESS_604631] use at enrollment visit (Week 52) will take place 
under guidance and the supervision of one site staff member. At the enrollment visit (Week 52) 
the site staff will walk subjec ts through the “Instructions For Use” on how to self -inject via 
PFS.  At the following visits, subjects will receive the PFS and instructions at the study site to follow on their own. 
NOTE: The needle cover of the syringe contains dry rubber (latex), which should not be handled 
by [CONTACT_471734]. During the treatment period from Week 52 until Week 256, subjects will receive a maximum  
of 104 study treatment injections (2 injections of secukinumab 150 mg PFS and/or placebo PFS at each vi sit).  The actual number of study treatment injections will depend on the treatment 
assigned.  All subjects will receive 52 study treatment injections between Week 52 and Week 152 (2 injections of secukinumab 150 mg PFS and/or placebo PFS at each visit); between Week 156 and 256 subjects could receive as many as 52 study treatment injections (2 injections of secukinumab 150 mg PFS every four weeks) or as few as 0 study treatment injections (SoR treated subjects who do not meet start of relapse criteria at any point). 
At study visits when pre -dose blood samples have to be drawn ( Table 6 -1), the study treatment 
will be injected to the subject only after the blood samples have been taken.  At each visit, all study assess ments, including the completion of Patient Reported Outcomes 
(PROs), should be completed prior to the self injection of study treatment. After Week 256, no further study treatment will be administered during the treatment period. 
In addition, no study trea tment is administered during the follow -up period and follow -up [ADDRESS_604632] the investigator if he/she is unable for any reason to 
attend a study visit as scheduled.  
All dates, times of injections, mode of injection (self or by [CONTACT_108575]) during the study 
must be recorded on the Dosage Administration Record eCRF.  Immediately before dispensing the package for injection, investigator staff will detach the outer part of the label from the packaging and affix i t to the source document (Drug Label Form) for that subject’s unique 
subject number. 
The investigator should promote compliance by [CONTACT_90192]’s  safety and the validity 
of the study. 
Administration  
Secukinumab solution for s.c. injection or placebo secukinumab solution (active or placebo, 
respectively) will be provided in a PFS. 
The study treatment solution must be injected in non- affected areas o f the skin. If possible, 
throughout the trial administer the study treatment to one of the following body regions, 
changing the injection site from visit to visit: right thigh, left thigh, right stomach, left stomach, upper outer arm (when assisted by [CONTACT_471735]). 
[COMPANY_001]  Confidential  Page 35  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
Prior to administration the boxes containing the PFS with study treatment solution should be 
allowed to come to room temperature unopened for about 20 minutes before administration. Used PFS should be disposed immediately after use in a sharps cont ainer OR according to the 
regulatory needs of the respective countries. 
Home administration 
After Week 156 (two years of self -administered study treatment under the supervision of site 
staff), subjects will be expected to self -administer the PFS at home wh en they are not visiting 
the site for any other trial related procedure. Subjects must be instructed to contact [CONTACT_1275]/site staff prior to any self -administration if they have any AEs or SAEs to report. 
The subjects will be allowed to self -admini ster treatment at home only if they have exhibited 
correct self -administration of the PFS at the site.  If the subject is not able or not willing to self -
administer the PFS, he or she should visit the site every [ADDRESS_604633] will administer the study drug at the site.  However, during those visits 
no other assessments will be performed other than checking vitals (recorded in source) and checking for AEs or SAEs.  
5.5.[ADDRESS_604634] enrolls in the extension study (CAIN457A2304E1).   
The investigator should instruct the subject to notify the study site about any new treatments 
he/she takes after the start of study treatment. All medications and significant non -drug 
therapi[INVESTIGATOR_014] (including physical therapy and blood transfusions) administered after the subject 
started study treatment must be listed on the Concomitant medications eCRF or Surgeries and Medical Procedures eCRF. Start date, end date, unit, frequency, route and reason for administration or change are to be recorded.  
The investigator should instruct the patient to notify the study site about any new medications he/she takes after the patient was enrolled into the study. All medications, procedures and significant non- drug therapi[INVESTIGATOR_014] (including physical therapy and blood transfusions) administered 
after the patient was enrolled into the study mus t be recorded.  
[COMPANY_001]  Confidential  Page 36  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
5.5.8  Prohibited Treatment  
The use of concomitant medication for psoriasis in all body regions (except face, scalp, and/or 
genitoanal area as noted below) is restricted to bland emollients (not supplied by [CONTACT_5343]) and 
other non- medicated interv entions. Use of bland emollients must be recorded on the 
Concomitant medications eCRF.  
The definition of “bland” excludes all topi[INVESTIGATOR_471709] (but not limited to) lactic acid, salicylic acid, ur ea, α- hydroxy acids or fruit 
acids.  
The use of bland emollients should be avoided during the 12 hours preceding a scheduled study visit.  
Topi[INVESTIGATOR_11977] (CS) treatment, or use of other topi[INVESTIGATOR_471710], is not allowed for treatment of psoriasis, except when applied 
to the face, scalp, and/or genitoanal area for ≤14 consecutive days. Topi[INVESTIGATOR_471711] d for ≤14 
consecutive days. 
Subjects need to be advised to limit exposure to ultraviolet (UV) light (including sunbathing 
and/or use of UV tanning devices) during the study to avoid possible effect on psoriasis. 
The investigator should instruct the subject  to notify the study site about any new treatments 
he/she takes after the start of the study treatment.  All prohibited medications and significant 
non-drug therapi[INVESTIGATOR_471712] e Concomitant medications eCRF or the Surgeries and Medical Procedures eCRF.  
Use of any treatments displayed in Table 5 -4 that could confound the efficacy is NOT allowed 
for any indication during the study excluding tre atment -free follow -up 2 period. 
Table 5-4 Prohibited treatment  
Prohibited treatments†,‡  
Alefacept, briakinumab, efalizumab, ustekinumab  
Biological immunomodulating agents other than above (e.g., adalimumab, etanercept, 
infliximab)  
Other systemic immunomodulating treatments§ (e.g., MTX, cyclosporine A, 
corticosteroids§, cyclophosphamide)  
Other systemic psoriasis treatments* (e.g. retinoid s, fumarates)  
Photochemotherapy (e.g., PUVA)  
Phototherapy (e.g., UVA, UVB)  
Use of topi[INVESTIGATOR_471713] > 14 
consecutive days*  (e.g., corticosteroids [CS], vitamin D analogues, pi[INVESTIGATOR_031], retinoids, salicylvaseline, salicylic acid, lactic acid,  tacrolimus, tar, urea, α -hydroxy or fruit 
acids)  
Live virus vaccinations during extension study  
[COMPANY_001]  Confidential  Page 37  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
Prohibited treatments†,‡  
Any investigational treatment or participation in any interventional clinical trial during 
extension  trial 
†If a subject inadvertently used the prohibited treatment in the core study (e.g. CAIN457A2304 or 
CAIN457A2307) without undue safety risk till completion of Week 52, eligibility will need to be 
discussed with the global clinical team.  
‡In case of undue safety risk for the subject, the subject should discontinue study treatment at the 
discretion of the investigator. If the subject received a live virus vaccination during the study, the subject must discontinue study treatment
. 
§Inhalative CS with on ly a topi[INVESTIGATOR_191281] (e.g., to treat asthma) are not considered “ systemic 
immunomodulating treatments” and are therefore acceptable as co- treatment  
*There is no restriction on the use of anti -histamines or the use of corticosteroids in the eye or ear.  
5.5.[ADDRESS_604635]’s premature withdrawal from the study and r ecord 
this information on the end of treatment (EOT) eCRF (Week 260). 
Study treatment must be discontinued under the following circumstances: 
• Withdrawal of informed consent 
• Emergence of the following adverse events: adverse events that in the judgment of t he 
investigator, taking into account the subject’s overall status, prevent the subject from 
continuing participation in the study (for example, sepsis or serious infection).  
• Any laboratory abnormalities that in the judgment of the investigator, taking into  consideration the subject’s overall status, prevents the subject from continuing participation in the study.  
• Pregnancy (see Section 6.5.6 and Section 7.4) 
• Continued use of prohibited treatment as per recommendations in Table 5 -4. 
• Any other protocol deviation that results in a significant risk to the subject’s safety 
In addition to the requirements mentioned above for study treatment discontinuation, the investigator should discontinue study treatment for a given subject if, on balance, he/she believes that continuation would be detrimental to the subject’s well- being.  
Subjects who discontinue study treatment should NOT be considered withdrawn from the study. These subjects should have all Week [ADDRESS_604636] dose of secukinumab and then enter the treatment -free follow -up period 
(Weeks 264 and 268). Subsequently, these subjects should enter the follow -up 2 period. On the 
EOT eCRF (Week 260), the site staff must record the date and primary reason for stoppi[INVESTIGATOR_262].  
[COMPANY_001]  Confidential  Page [ADDRESS_604637]’s premature withdrawal from the study and record this information on t he applicable 
end of study period eCRF (Follow -up period completion eCRF [Week 268] or Follow -up 2 
period completion eCRF, respectively). 
Patients who withdraw from the follow -up period should perform the Week 268 assessments 
(see Table 6 -1). 
Premature subject withdrawal  
Subjects who state an intention to withdraw prematurely from the study will be asked to return 
for follow -up visits to assess safety after cessation of therapy and, if willing, to assess duration 
of effect (e.g. rebound assessments). If the subject returns to the study site to have his/her follow-up visits, the investigator will follow the study treatment discontinuation procedures. 
The investigator must contact [CONTACT_471736] c ompletes the assessments on visit of 
Week [ADDRESS_604638]’s early completion of the study due to subject withdrawal. 
Lost to follow -up 
For subjects who are lost to follow -up (i.e. those subjects whose status is unclear because they 
fail to appear for study visits without stating an intention to withdraw), the investigator should 
show “due diligence” by [CONTACT_144956], e.g. dates of telephone calls, registered letters, etc.  
5.5.[ADDRESS_604639] often, study treatment discontinuation and knowledge of the possible treatment assignments a re sufficient to treat a study patient who presents with an 
emergency condition. Emergency treatment code breaks are performed using the IRT. When the investigator contacts the system to break a treatment code for a patient, he/she must provide the request ed patient identifying information and confirm the necessity to break the treatment 
code for the patient. The investigator will then receive details of the investigational drug treatment for the specified patient and a fax or email confirming this information. The system 
[COMPANY_001]  Confidential  Page 39  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
will automatically inform the [COMPANY_001] monitor for the site and the global study lead that the 
code has been broken. 
It is the investigator’s responsibility to ensure that there is a procedure in place to allow access 
to the IRT   in case of  emergency. The investigator will inform the patient how to contact [CONTACT_5657]/her 
backup in cases of emergency when he/she is unavailable. The investigator will provide protocol number, investigational treatment name [CONTACT_90228], patient number, and instructions for contact[CONTACT_144957] (or any entity to which it has delegated responsibility for emergency code breaks) to the patient in case an emergency treatment code break is required at a time when the investigator and backup are unavailable. 
Study treatment must be discontinued after emergency unblinding. 
The appropriate personnel from the study site and [COMPANY_001] will assess whether study treatment 
should be discontinued for any subject whose treatment code has been broken inadvertently for any re ason. 
Subjects who are prematurely unblinded will be discontinued from the study treatment and requested to return for the end of the treatment period visit (Week 260) , two follow -up visits 
and follow-up [ADDRESS_604640] -study treatment  
• A subject entering into CAIN457A2304E1 will be said to have completed the extension 
study after he/she has completed all visits and assessments as defined in Table 6 -1 and 
received all doses of the study treatment in accordance with the protocol.  
• The extension study as a whole will be considered complete when all eligible subjects rolled over from the core study (e.g., CAIN457A2304 or CAIN457A2307) have completed as per protocol the visits and assessments defined in Table [ADDRESS_604641] refer them for appropriate ongoing care. Subjects who 
complete CAIN457A2304E1 may be eligible to enter another planned extension trial. 
5.5.12  Early study termination  
The study can be terminated at any time for any reason by [CONTACT_5343]. Should this be necessary, 
the patient should be seen as soon as possible and properly managed for a prematurely withdrawn patient. The investigator may be informed of additional procedures to be followed in order to ensure that adequate consideration is given to the protection of the patient’s interests. The investigator will be responsible for informing IRBs and/or ECs of the early termination of the trial.  
6 Visit schedule and assessments  
Table 6 -1 Assessment Schedule lists all of the assessments and indicates with an “x” when the 
visits are performed.  
[COMPANY_001]  Confidential  Page 40  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
Subjects should be seen for all visits on the designated day within the allowed “visit window” 
specified below or as close to it as possible.  
During the treatment period, subjects may be seen at an unscheduled visit, e.g. if they experience deterioration of psoriasis, or AEs that in the opi[INVESTIGATOR_279828]. During these unscheduled visits, study treatment will NOT be administered. A visit window of “±5” will be allowed for Week [ADDRESS_604642] study  treatment administration, at which time all the assessments listed 
for EOT (Week 260) will be performed (see Section 5.5.10). Subjects will return to the study 
site for further assessments as indicated under the f ollow- up visits (Weeks 264 and 268) (see 
Section 3.1).  
Only subjects who prematurely discontinued study treatment should enter follow -up 2 period 
after completion of follow -up visits (Weeks 264 and 268). Follow -up [ADDRESS_604643] them or a knowledgeable informant by [CONTACT_109034] (i.e. certified letter) immedi ately. At this contact, the 
safety (e.g., potential occurrence of AE or SAE) and the primary reason for a subject’s premature withdrawal should be determined. 
At a minimum, subjects will be contact[CONTACT_356253] [ADDRESS_604644]. 
Order of assessments:  
• Subject to complete QoL tools prior to any investigator assessments. Order of QoL tools 
is: DLQI, EQ -5D, HAQ-DI (subjects with history of PsA only but not applicable to 
subjects from the CAIN457A2307 core study) 
• Investigator to complete investigator assessments. Order is:  
1. IGA 
2. PASI  
• All remaining study visit procedures (e.g., laboratory sample collection, vital signs 
measurements) must be completed prior to study treatment dosing.  
• Enter PASI and IGA assessments into eCRFs BEFORE contact[CONTACT_471737]  
• Contact [CONTACT_471738].  
[COMPANY_001]  Confidential  Page 41  
Amended Protocol v02 C lean  Protocol No. CAIN457A2304E1  
Table 6-1 Assessment schedule  
 Treatment Period (Years 1 and 2)  
 Unscheduled visit  Week (Relative to Baseline of 
core studies)  52a 
Core 52a 
Ext 56 60 64 68 72 76 80 84 88 92 96 100 104 108 112 116 120 124 128 132 136 140 144 148 152 156 
 
Visit window (in days)  ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5  
Day 365 365 393 421 449 477 505 533 561 589 617 645 673 701 729 757 785 813 841 869 897 925 [PHONE_9864]  1037  1065  1093   
In office visit - all subjects  x x x x x x x x x x x x x x x x x x x x x x x x x x x x  x 
Obtain informed consent  x                           Continue with Week 160   
Inclusion/exclusion criteria1  x                            
Concomitant medications  x x x x x x x x x x x x x X x x x x x x x x x x x x x X x 
Physical examination x x x x x x x x x x x x x X x x x x x x x x x x x x x X (x) 
Weight x    x   x   x    x   x   x   x    X  
Vital signs  x  x x x x x x x x x x x X x x x x x x x x x x x x x X x 
Urinalysis (local)  x    x   x   x    x   x   x   x    X  
Lab analysis:  
chemistry and hematology2 x  x x x x x x x x x x x X x x x x x x x x x x x x x X x 
Fasting Labs: lipid panel2 x       x       x      x       X  
Fasting Labs:  
plasma glucose [ADDRESS_604645] (local)4 x    x   x   x    x   x   x   x    X  
ECG (standard 12 lead)  x    x   x   x    x   x   x   x    X  
Blood sample for IG5,6 x       x       x      x       X x5,6 
Blood sample for PK5,6 x    x   x       x   x   x       X x5,6 
PASI  x  x x x x x x x x x x x X x x x x x x x x x x x x x X  x 
IGA mod  2011  x  x x x x x x x x x x x X x x x x x x x x x x x x x X x 
Adverse event (AE) 
assessment  x  x x x x x x x x x x x X x x x x x x x x x x x x x X x 
EQ-5D x    x   x   x    x   x   x   x    X  
[COMPANY_001]  Confidential  Page 42  
Amended Protocol v02 C lean  Protocol No. CAIN457A2304E1  
 Treatment Period (Years 1 and 2)  
 Unscheduled visit  Week (Relative to Baseline of 
core studies)  52a 
Core 52a 
Ext 56 60 64 68 72 76 80 84 88 92 96 100 104 108 112 116 120 124 128 132 136 140 144 148 152 156 
 
Visit window (in days)  ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5  
Day 365 365 393 421 449 477 505 533 561 589 617 645 673 701 729 757 785 813 841 869 897 925 [PHONE_9864]  1037  1065  1093   
DLQI  x    x   x   x    x   x   x   x    X  
HAQ -DI8 x    x   x   x    x   x   x   x    X  
Serious AE assessment  x  x x x x x x x x x x x X x x x x x x x x x x x x x X x 
Completion call for core study  x                             
Complete PASI and IGA 
eCRF and call IRT   x x x x x x x x x x x x X x x x x x x x x x x x x x X  
Dispense Investigational 
Treatment   x x x x x x x x x x x x X x x x x x x x x x x x x x x  
 
[COMPANY_001]  Confidential  Page 43  
Amended Protocol v02 C lean  Protocol No. CAIN457A2304E1  
 
 
 Treatment Period (Years 3 and 4)  Unscheduled visit11 Follow- up 
period  Follow-
up 2 
Period  
Week (Relative 
to Baseline of core studies)  160 164 168 172 176 180 84 188 192 196 200 204 208 212 216 220 224 228 232 236 240 244 248 252 256 260 264 
/F4 268 
/F8 Phone 
call 
every 3 
months  
Visit Window (in 
days)  ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5  
Days  1121 1149 1177 1205 1233 1261 1289 1317 1345 1373 1401 1429 1457 1485 1513 1541 1569 1597 1625 1653 1681 1709 1737 1765 1793 1821 1849 1877  
In office visit if every 4 wks 
dosing    x   x   x    x   x   x   x      x x  
Home administration if every 4 wks 
dosing  x x  x x  x x  x x x  x x  x x  x x  x x x      
In office visit if 
SoR dosing  x x x x x x x x x x x x x x x x x x x x x x x x x  x x x  
Concomitant 
medications  x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x 
Physical 
examination   x   x   x    x   x   x   x    x (x) x x  
Weight                          x   x  
Vital signs  O O x O O x1 O O x O O O x O O x O O x O O x O O O x x x x  
Urinalysis 
(local)    x   x   x    x   x   x   x    x   x  
Lab analysis:  
chemistry and 
hematology2      x       x      x       x x x x  
Fasting Labs:  
lipid panel2                          x   x  
Fasting Labs:  
plasma glucose 
2      x       x      x       x   x  
[COMPANY_001]  Confidential  Page 44  
Amended Protocol v02 C lean  Protocol No. CAIN457A2304E1  
 Treatment Period (Years 3 and 4)  Unscheduled visit11 Follow- up 
period  Follow-
up 2 
Period  
Week (Relative 
to Baseline of core studies)  160 164 168 172 176 180 84 188 192 196 200 204 208 212 216 220 224 228 232 236 240 244 248 252 256 260 264 
/F4 268 
/F8 Phone 
call 
every 3 
months  
Visit Window (in 
days)  ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±[ADDRESS_604646] 
(local)4   x   x   x    x   x   x   x    x   x  
ECG (standard 
12 lead)       x       x      x       x   x  
Blood sample 
for IG5,6             x             x x5,6  x  
Blood sample 
for PK5,6             x             x x5,6  x  
PASI  O O x O O x O O x O O O x O O x O O x O O x O O O x x x x  
Assessment of 
rebound 
symptoms7                          x x7 x x  
IGA mod  2011    x   x   x    x   x   x   x    x x x x  
Adverse event 
(AE) 
assessment  O O x O O x O O x O O O x O O x O O x O O x O O O x x x x x 
DLQI    x   x   x    x   x   x   x    x     
HAQ -DI8   x   x   x    x   x   x   x    x     
Serious AE 
assessment  O O x O O x O O x O O O x O O x O O x O O x O O O x x x x x 
Complete PASI (and IGA
9) 
eCRF and call 
IRT  O O x O O x O O x O O O x O O x O O x O O x O O O x     
[COMPANY_001]  Confidential  Page 45  
Amended Protocol v02 C lean  Protocol No. CAIN457A2304E1  
 Treatment Period (Years 3 and 4)  Unscheduled visit11 Follow- up 
period  Follow-
up 2 
Period  
Week (Relative 
to Baseline of core studies)  160 164 168 172 176 180 84 188 192 196 200 204 208 212 216 220 224 228 232 236 240 244 248 252 256 260 264 
/F4 268 
/F8 Phone 
call 
every 3 
months  
Visit Window (in 
days)  ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5  
Days  1121 1149 1177 1205 1233 1261 1289 1317 1345 1373 1401 1429 1457 1485 1513 1541 1569 1597 1625 1653 1681 1709 1737 1765 1793 1821 1849 1877  
Dispense Investigational 
Treatment 10 O O x O O x O O x O O O x O O x O O x O O x O O O x     
End of Treatment Period (EOT) eCRF and call 
IRT                          x     
Follow -up 
Period completion  
eCRF                              x  
Follow -up 2 
Period completion  
eCRF                               x 
 
eCRF:electronic case report form; PK:pharmacokinetics; IG:immunogenicity  
O: assessment completed for subjects with protocol -mandated in- office visits in between Week 160 and 256.  
*The screening period will be the duration between signing the informed consent form and enrollment registered with Interactive response technology 
(IRT).  Subjects must sign the informed consent form after completing the core study Week 52 assessments.  
a Enrollment into the extension study occurs on the same day (Week 52) as the end of maintenance period of the core study CAIN457A2304 or 
CAIN457A2307 (±5 days).  The column for Week ‘52 core’ represents assessments that will be done during the CAIN457A2304 core Week 52 visit or the 
CAIN457A2307 Week 40 visit.  These assessments will be entered in the core study eCRFs.  The column Week ’52 ext’ represents assessments that 
will be done for the CAIN457A2304E1 study.   
1These assessments are supported by [CONTACT_121951]. However, data regarding to which Inclusion/Exclusion criteria are 
not met are captured on the Inclusion/Exclusion Screen eCRF.  
[ADDRESS_604647] at end of maintenance period (Week 52) of core st udy is 
positive. The study drug treatment should not be given until the results confirm that subject is not pregnant.  
[ADDRESS_604648] an IG or PK sample not taken at a regular scheduled visit. (If an IG sample is taken, a 
PK sample must accompany the IG sample.)  
[ADDRESS_604649] be called within two days and the reason for not being enrolled will be entered o n the Screening Phase Disposition electronic Case Report Form 
(eCRF). The Screening visit date, Informed Consent eCRF, Inclusion/Exclusion Criteria eCRF must be completed. If the subject has any SAE in the screening period (between signing the ICF and being enrolled), the Adverse Event eCRF and a paper SAE form must be completed.  
If a subject fails to be treated in the extension study, the subject completes the follow -up visits 
in the respective core study.  
The Withdrawal of consent eCRF should be completed if consent was withdrawn during the 
screening period before the subject was enrolled. The Death eCRF should be completed in the case of a death during the screening period. 
6.2 Patient demographics/other baseline characteristics 
The following information will be based on information derived from core study CAIN457A2304 or CAIN457A2307.  This information will not be reentered into the CAIN457A2304E1 eCRFs. 
Subject demographic and baseline characteristic data to be collected on all subjects include: 
date of birth, age, sex, race, ethnicity, source of subject referral, and on -going concomitant 
medications (relative to core studies) present before signing informed consent for this extension study.  
6.[ADDRESS_604650] or the qualified site personnel. 
6.4 Efficacy 
All efficacy assessments should be performed prior to administration of study treatment.  
It is important to perform the IGA before the PASI,  as the knowledge of PASI scoring can 
potentially influence how the evaluator  scores the IGA. Therefore, the following order should 
be applied when performing the efficacy assessments during study visits:  
• Investigator’s Global Assessment (IGA mod 2011; scale from 0 – 4)  
• Psoriasis Area and Severity Index (PASI; score from 0 – 72) 
• Rebound assessment  
[COMPANY_001]  Confidential  Page 48  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 6.4.1  Investigator’s global assessment (IGA mod 2011)  
IGA mod 2011 will be conducted for overall psoriatic disease as indicated in Table 6 -1.  It is 
recommended that the same evaluator conducts the asses sment throughout the study whenever 
possible. 
The IGA mod 2011 rating scale for overall psoriatic disease is shown in Table 6 -2 The IGA 
mod 2011 rating scale . 
The IGA mod 2011 scale has been used in the  core studies CAIN457A2304 and 
CAIN457A2307, and is a modified version of the scale used in secukinumab phase II studies; 
it was developed in collaboration with health authorities. 
The IGA mod [ADDRESS_604651]’s disease 
state at the time of the assessments, and does not attempt a comparison with any of the subject’s 
previous disease states, whether at baseline or at a previous visit.  
The IGA mod [ADDRESS_604652] clear  Normal to pi[INVESTIGATOR_108997]; no thickening; no to minimal  
focal scaling  
2 Mild Pi[INVESTIGATOR_22767]; just detectable to mild thickening;  
predominantly fine scaling  
3 Moderate  Dull bright red, clearly distinguishable erythema; clearly 
distinguishable to moderate thickening; moderate scaling  
4 Severe  Bright to deep dark red coloration; severe thickening with hard 
edges; severe / coarse scaling covering almost all or all lesions  
Note: Involvement of nails is not part of the assessment.  
Based on this scale, a subject will be considered as IGA [ADDRESS_604653] two points on the IGA scale compared to baseline. 
6.4.2  Assessment of the psoriasis area and severity index (PASI)  
The in vestigator or qualified designee will complete the PASI assessment as indicated in Table 
6-1. Whenever possible, the same evaluator should perform this assessment at all visits. 
A PASI score ( Fredriksson and Pettersson 1978, Weisman et al 2003 , Gottlieb et al 2005 ) will 
be derived as indicated in Table 6 -3. The head, trunk, upper limbs and lower limbs are assessed 
separately for erythema, thickening (plaque elevation, induration), and scaling (desquamation). 
The average degree of severity of each sign in each of the four body regions is assigned a score of 0-4. The area covered by [CONTACT_109042] a percentage of the total 
area of that particular body region. Further practical details help the assessment:  
1. The neck is assessed as part of the head.  
[COMPANY_001]  Confidential  Page 49  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 2. The axillae and groin are assessed as part of the tr unk. 
3. The buttocks are assessed as part of the lower limbs. 
4. When scoring the severity of erythema, scales should not be removed. 
Table 6-3 The PASI scoring system  
Body region  Erythema  (E)  Thickening     
(plaque elevation, induration, I)  Scaling (desquamation) (D) Area score (based on true area %, A)*  
Head (H)**  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0 = 0%  
1 = 1 -9% 
2 = 10- 29% 
3 = 30- 49% 
4 = 50- 69% 
5 = 70- 89% 
6 = 90- 100%  
 
Trunk (T)***  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0 = 0%  
1 = 1 -9% 
2 = 10- 29% 
3 = 30- 49% 
4 = 50- 69% 
5 = 70- 89% 
6 = 90- 100%  
 
Upper limbs (U)  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0 = 0%  
1 = 1 -9% 
2 = 10- 29% 
3 = 30- 49% 
4 = 50- 69% 
5 = 70- 89% 
6 = 90- 100%  
 
Lower limbs (L)  
**** 
 0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0 = 0%  
1 = 1-9% 
2 = 10- 29% 
3 = 30- 49% 
4 = 50- 69% 
5 = 70- 89% 
6 = 90- 100%  
* Percentage (not score) of body region (not whole body) affected will be entered in the eCRF  
**Neck is assessed as part of the Head (H) body region.  
***Axillae and groin are assessed as part of the Trunk (T) body region.  
[COMPANY_001]  Confidential  Page 50  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 ****Buttocks are assessed as part of the Lower limbs (L) body region.  
Because the head and neck, upper limbs, trunk and lower limbs correspond to approximately 
10%, 20%, 30% and 40% of the body surface area, respectively, the P ASI score is calculated 
using the formula: PASI = 0.1(EH+IH+DH)AH + 0.2(EU+IU+DU)AU + 0.3(ET+IT+DT)AT + 
0.4(EL+IL+DL)AL  
The keys for the letters are provided in Table [ADDRESS_604654].  
Definitions of efficacy variables based on PASI  
The following definitions are used in this study (see CHMP guidelines for psoriasis 
(CHMP/EWP/2454/02 2004)), baseline referring to randomization visit in CAIN457A2304: 
• PASI 50 response: subjects achieving ≥ 50% improvement (reduction) in PASI score compared to baseline are defined as PASI 50 responders  
• PASI 75 response:  subjects achieving ≥ 75% improvement (reduction) in PASI score 
compared to baseline are defined as PASI 75 responders 
• PASI 90 response:  subjects achievi ng ≥ 90% improvement (reduction) in PASI score 
compared to baseline are defined as PASI 90 responders 
• PASI 100 response/remission:  complete clearing of psoriasis (PASI=0)  
• Relapse: when the achieved maximal PASI improvement from baseline is reduced by >50%  
• In addition to the above, the following definition is also used in this protocol: 
• Start of relapse:  loss of  ≥20% of the maximum PASI gain in CAIN457A2304 or 
CAIN457A2304E1 (compared to baseline of the core study) achieved at any time before the visit at w hich the assessment is made and loss of PASI 75 response 
• PASI Partial response:  Subjects achieving at least 50%, but less than 75% reduction of 
PASI compared to baseline (i.e PASI 50 but not a PASI 75 response) 
• PASI Non response:  Subjects achieving less than 50% reduction of PASI compared to 
baseline  
[COMPANY_001]  Confidential  Page 51  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 [IP_ADDRESS]  Assessment of rebound  
Rebound of disease will be assessed as indicated in Table 6 -1. 
In addition, to the assessment of PASI, the investigator will assess whether new pustular 
psoriasis, or new erythrodermic psoriasis, or more inflammatory psoriasis occurred (yes/no). 
6.4.[ADDRESS_604655]’s body area is affected by [CONTACT_90050], is mandated by [CONTACT_471739] (CHMP guideline on the treatment of psoriasis- CHMP/EWP/2454/02 2004).  
6.5 Safety  
All blood draws and safety assessments should be done prior to study treatment administration. Appropriate safety assessments (e.g. evaluation of AEs and SAEs including injection site reactions) should be repeated after the dose is administered. 
• Evaluation of all AEs and SAEs including inject ion site reactions  
• Physical examination  
• Vital signs  
• Laboratory evaluations  
• Hematology  
• Clinical chemistry  
• Urinalysis  
• Immunogenicity (assessment of anti-secukinumab antibody development) 
• Electrocardiogram  
• Pregnancy and assessments of fertility  
For frequency of assessments, s ee Table [ADDRESS_604656]’s 
eCRF. Significant findings made after signing informed consent which meet the definition of an Adverse Event must be recorded on the Adverse Event screen of the subject’s eCRF ( Section 
7). 
[COMPANY_001]  Confidential  Page 52  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 6.5.2  Vital signs  
Vital signs (including blood pressure and pulse measurements) will be assessed at every 
scheduled visit as indicated in Table [ADDRESS_604657] has been sitting for five minutes, with back supported and both feet placed on the floor, systolic and diastolic blood pressure will be measured twice (measurements separated by 1 to 2 minutes) using a validated device, with an appropriately sized cuff.  In case the cuff sizes available are not large enough for the subject's arm circumference, a sphygmomanometer with an appropriately sized cuff may be used ( Mancia et al 2007 ). On the Vital Signs eCRF, the 
average of the two measurements will be entered. If possible, assessments should be performed 
by [CONTACT_109047].  
Normal blood pressure will be defined as a systolic pressure of 90 to <120 mmHg, and a diastolic blood pressure of 60 to <80 mmHg under the measurement conditions outlined above. Notable blood pressure will be hypertension (systolic ≥140 mmHg and/or diastolic ≥ 90 mmHg) or hypotension (systolic <90 mmHg and/or diastolic <60 mmHg). A blood pressure indicative of prehypertension (systolic 120 to < 140 mmHg and/or diastolic 80 to < 90 mmHg) will not be regarded as notable ( Chobanian et al 2003). A normal pulse rate will be defined as a rate of 60 
to 100 beats per minute under the measurement conditions outlined above. Notable pulse rates are a rate below  60 bpm (bradycardia) or above 100 bpm (tachycardia). 
The investigator will decide whether action needs to be taken to address notable vital signs, taking into account the overall status of the subject. No specific action is foreseen as part of the study p rotocol. 
6.5.3  Height and weight  
Height and weight will be based on information derived from core study CAIN457A2304 or CAIN457A2307.  This information will not be reentered into the CAIN457A2304E1 eCRFs at Week 52 (enrollment) and body weight will be measured a s listed in Table [ADDRESS_604658]. No specific action is foreseen as part of the study protocol. 
[COMPANY_001]  Confidential  Page 53  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 [IP_ADDRESS]  Hematology  
Hemoglobin, hematocrit, red blood cell count, white blood cell count with differential 
(neutrophils including bands, lymphocytes, monocytes, eosinophils, basophils) and platelet count will be measured at all scheduled study visits, within the visit window specified in Table 
6-1. 
[IP_ADDRESS]  Clinical chemistry  
Serum chemistries will include urea, creatinine, total bilirubin, AST (SGOT), ALT 
(SGPT),GGT, alkaline phosphatase, sodium, potassium, bicarbonate, calcium, phosphorous, 
total protein, albumin, and uric acid. Serum chemistries will be measured at all scheduled study visits within the visit window specified in Table 6 -1. 
[IP_ADDRESS]  Urinalysis  
Dipsticks will be provided by [CONTACT_471740]. The sites will record the results in the appropriate eCRF page for each subject.  
Standard dipstick measurements for specific gravity, protein, glucose, pH, blood, urine blood dipstick (non- hemolyzed), urine blood dipstick (hemolyzed), bilirubin, ketones and WBC will 
be done at scheduled visits as indicated in Table 6 -1. 
[IP_ADDRESS]  Immunogenicity (IG)  
Blood samples for IG (anti -secukinumab antibodies) will be taken pre -dose at the scheduled 
timepoints as indicated in Table 6 -1 and Table 15 -2. Blood samples (approximately 2 mL) will 
be collected into serum separator tubes (SST). The blood sample will be allowed to clot over a minimum of 30 minutes at room temperature prior to harvesting of the serum. The serum will be obtained by [CONTACT_279880] 2500 revolutions per minute (rpm) for 10 minutes.  
Serum samples will be placed on ice, split into 2 aliquots (labeled plain barrier polypropylene tubes) and then stored (within 30 minutes of collection) at approximately -70°C to -20°C prior 
to shipment on dry ice to the central laboratory. Shipment of stored aliquots from the site to the central lab should be on a monthly basis. To the extent possible, the site should send each aliquot to the central laborat ory separately. If a study site does not have the facility to store aliquots at 
the conditions specified, then they will maintain the sample on dry ice at the site and ship on dry ice on the day of collection. The central lab will ship one aliquot of the samples on dry ice to the analytical laboratory. The remaining aliquots must be kept at the central lab as a backup sample. Remaining samples will only be disposed of after approval by [CONTACT_471741] (typi[INVESTIGATOR_897] 6 to 12 months after the clinical study  report [CSR] is published). 
All blood samples will be taken by [CONTACT_37277]. The actual sample collection date and exact time of collection will be entered on the Blood collection for IG eCRF or the unscheduled blood collection for IG eCRF, as appropriate. Sampling problems will be noted in the ‘Reason sample not taken’ section of the eCRF. 
A laboratory manual will be provided by [CONTACT_279886], sample handling and shipment. 
[COMPANY_001]  Confidential  Page 54  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 Tubes and labels will be provided by [CONTACT_37281]/sample type and sample 
number preprinted on the label. 
Further details on labeling of the IG samples can be found in Appendix 4, Section 16.1.1 
6.5.5  Electrocardiogram (ECG) 
A standard 12- lead ECG will be performed as indicated in Table [ADDRESS_604659]'s source documents. 
All ECGs must be performed on the ECG machines provided to the study site. All ECGs will 
be independently reviewed by a central reader. Instructions for the collection and transmission of the ECGs to the independent reviewer will be provided in the ECG investigator manual.  
Even though there is no exclusion criterion specifically based on the ECG, clinically significant findings from the ECG assessment made at Week [ADDRESS_604660] from participating in the study (taking into account the subject's overall status as well as the medication profile), the subject s hould not receive study treatment. 
6.5.[ADDRESS_604661] is positive (based on serum β- hCG as defined by 
[CONTACT_15622]) at the Enrollment Visit Week [ADDRESS_604662] be discontinued from  the trial (as per Section 
5.5.10) 
6.5.[ADDRESS_604663] measures for a biologic 
immunomodulating agent in psor iasis.  
6.6 Other assessments  
These include (as indicated in Table 6 -1) 
• Fasting laboratory evaluations,  
• Health -related quality of life assessments such as  
1. DLQI  
[COMPANY_001]  Confidential  Page 55  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 2. EQ-5D 
3. HAQ- DI (only in subjects with psoriatic arthritis fro m study CAIN457A2304, not 
CAIN457A2307) 
• PK assessments will be done as indicated in Table 6 -1.  
 
6.6.1  Fasting laboratory evaluations  
Fasting (8 hour duration with water ad libitum ) laboratory tests will be assessed as indicated in 
Table 6 -1. 
Subjects should avoid smoking within the hour preceding the blood draws. 
A central laboratory will be used  for analysis of all fasting laboratory specimens. Details of the 
collections, shipment of samples and reporting of results by [CONTACT_471742]. 
[IP_ADDRESS]  Plasma glucose  
Fasting plasma glucose will be taken as a fasting blood sample at scheduled visits as indicated 
in Table 6 -1. 
[IP_ADDRESS]  Lipid panel  
A lipid profile including High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), 
cholesterol, triglycerides, lipoprotein (a), apolipoprotein B, apolipoprotein A -1, and adiponectin 
will be measured from a fasting blood sample at scheduled visits as indicated in Table [ADDRESS_604664]’s health- related quality of life will be 
assessed by [CONTACT_471743]: 
• Dermatology Life Quality Index (DLQI©) 
• EuroQOL 5- Dimension Health Status Questionnaire (EQ -5D©) 
• Health A ssessment Questionnaire- Disability Index (HAQ©-DI) (subjects with PsA from 
study CAIN457A2304 only) 
At the appropriate scheduled visits (see Table 6 -1), questionnaires are to be completed by [CONTACT_471744]/he is most facile, and before she/he sees the Investigator 
for clinical assessments. Responses will be collected using digitized paper with a digital pen. 
The digitized paper will serve as source documentation; the pen will be transfer red to its 
docking station for transmittal of the subject’s responses to the vendor’s database. Subjects are to complete the “Patient Reported Outcome (PRO) - Completion confirmation by [CONTACT_102]” 
page after completing all the questionnaires of a visit. This document will not be sent to the sponsor but kept at site in source documents. 

[COMPANY_001]  Confidential  Page [ADDRESS_604665]’s file as source documentation.  
Completed questionnaires will be reviewed and examined by a blinded staff member at the site 
(not the Investigator or eva luator of the subject for the physician assessments), before the 
clinical examination, for responses that may indicate potential AEs or SAEs. The Investigator is to review not only the responses to the questions in the questionnaires but also to look for unsolicited comments written by [CONTACT_423]. If AEs or SAEs are confirmed by [CONTACT_737], then she/he must record the events as per instructions given in Section 7  of the protocol. 
Investigators and study coordinators are not to encourage subjects to change the responses reported in the completed questionnaires. Study coordinators are to complete the header information at the top of the questionnaire prior to distributing it to the subjects. 
[IP_ADDRESS]  Dermatology Lif e Quality Index (DLQI)  
The Dermatology Life Quality Index (DLQI) is a 10 -item general dermatology disability index 
designed to assess health -related quality of life in adult subjects with skin diseases such as 
eczema, psoriasis, acne, and viral warts ( Finlay and Khan, 1994). The measure is self -
administered and includes domains of daily activities, leisure, personal relationships, symptoms 
and feelings, treatment, and work/school. The measure is widely used: it has been tested across 
[ADDRESS_604666] week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories, ranging from 0 (not at all) to 3 (very much). "Not  relevant" is also a valid response 
and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30 and higher scores indicate greater health -related quality -of-life impairment. Additionally, 
each subscale of the DLQI may be analyzed separately.  
The DLQI questionnaire (date of publication 1994) will be completed by [CONTACT_471745] 6 -1. 
[IP_ADDRESS]  EuroQOL 5 -Dimension (EQ -5D
©) Health Status Questionnaire  
EQ-5D© is a generic instrument to assess each subject’s health status. It provides a simple 
descriptive profile and a single index value for health status. The instrument essentially consists of 2 pages – the EQ -5D
© descriptive system and the EQ visual analog scale (VAS). The EQ-
5D© descriptive system comprises the following 5 dimensions: mobility, self -care, usual 
activities, pain/discomfort and anxiety/depression. 
Each dimension has 3 response levels: no problems, some problems, severe problems. The 
subject is asked to indic ate her/his health state by [CONTACT_13158] (or placing a cross) in the box against 
the most appropriate statement in each of the 5 dimensions. 
The VAS records the respondent’s self -rated health on a vertical scale where the endpoints are 
labeled ‘Best imaginable health state’ and ‘Worst imaginable health state’. This information 
can be used as a quantitative measure of health outcome as judged by [CONTACT_112775]. 
[COMPANY_001]  Confidential  Page 57  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 The EQ -5D© questionnaire (date of publication 1990) is to be completed by [CONTACT_471746] 6 -1. 
[IP_ADDRESS]  Health Assessment Questionnaire- Disability Index (HAQ©-DI) 
(subjects with PsA only)  
The Health Assessment Questionnaire (HAQ©) was developed by [CONTACT_471747]- term influence of chronic disease on a 
subject's level of functional ability and activity restriction. Although o riginally developed for 
use in subjects with rheumatic disease, the HAQ has been employed across a large variety of disease areas. The disability assessment component of the HAQ (Health Assessment Questionnaire© – Disability Index), the HAQ -DI, assesses a subject's level of functional ability 
and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 items in eight categories of functioning including dressing & grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. The stem of each item asks over the past week "Are you able to …" perform a particular task. Each item is scored on a 4 -point scale from 0 to 3, 
representing normal (without any difficulty [0]), with some difficulty (1), with much difficulty 
(2), and unable to do (3). The HAQ -DI also includes questions about the use of ‘aids or devices’ 
and aid from other people to supplement the answers given to the [ADDRESS_604667] as indicated in Table 6 -1 by [CONTACT_471748] a medical history of PsA recorded on the Psoriatic Arthritis History eCRF during the screening period of the CAIN457A2304 core study (subjects from the CAIN457A2307 study will not participate in the HAQ -DI questionnaire). 
6.6.[ADDRESS_604668] venipuncture. Blood samples (approximately 2 mL, 
not less than 1.5 mL) will be collected into SST tubes. The blood sample will be allowed to clot over a minimum of 30 minutes at room temperature prior to harvesting of the serum. The serum will be obtained by [CONTACT_279880] 2,500 rpm for 10 minutes. 
Serum samples will be placed on ice, s plit into 2 aliquots (polypropylene tubes) and then stored 
(within 30 minutes of collection) at -70°C to -20°C (approximately) prior to shipment to the 
central laboratory. Shipment of stored aliquots from the site to the central lab should be on a 
monthly basis. To the extent possible, the site should send each aliquot to the central laboratory 
separately. If a study site does not have the facility to store aliquots at the conditions specified, then samples must be stored on dry ice at the site and shipped on dry ice on the day of collection. The central lab will ship one aliquot of the samples on dry ice to the analytical laboratory. The remaining aliquots must be kept at the central lab as a backup sample. Remaining samples will 
[COMPANY_001]  Confidential  Page 58  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 only be disposed of after approval by [CONTACT_471741] (typi[INVESTIGATOR_897] 6 to 12 months after the 
Clinical study report (CSR) is published). 
The actual sample collection date and exact time of collection will be entered on the Blood 
collection for PK eCRF or the Unscheduled blood coll ection for PK eCRF, as appropriate. 
Sampling problems will be noted in the ‘Reason sample not taken’ section of the eCRF. 
PK sample handling, labeling and shipment instructions  
A laboratory manual will be provided by [CONTACT_279886], sample handling and shipment. Tubes and labels will be provided by [CONTACT_37281]/sample type and sample number preprinted on the label. 
Further details on labeling of the pharmacokinetics samples can be found in Appendix 4, 
Section 16.1.1 
PK sample stability   
AIN457 is stable in serum samples for 4 months at -20°C or at -80°C. Longer stability 
assessment is ongoing.  
PK analytical methods 
An ELISA method will be used for bioanalytical analysis of AIN457 in serum, with an 
anticipated lower limit of quantification (LLOQ) of 80 ng/mL. The detailed method description to assess AIN457 concentration will be described in the bioanalytical raw data of the study and in the respe ctive BDR.  
  
     
 
  
 
6.6.6  Other biomarkers  
Not applicable.  

[COMPANY_001]  Confidential  Page 59  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 7 Safety monitoring 
7.1 Adverse events 
An adverse event (AE) is any untoward medical occurrence (i.e., any unfavorable and 
unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or clinical investigation subject after providing written informed consent  for pa rticipation in the 
study. Therefore, an AE may or may not be temporally or causally associated with the use of a 
medicinal (investigational) product. 
The occurrence of adverse events should be sought by [CONTACT_105] -directive questioning of the patient 
at each offi ce visit or each telephone call during the study. Adverse events also may be detected 
when they are volunteered by [CONTACT_121966], laboratory test, or other assessments. Subjects must be instructed to contact [CONTACT_093]/site staff prior to any self -administration of study drug if they have any AEs or 
SAEs to report. 
Abnormal laboratory values or test results constitute adverse events only if they fulfill at least 
one of the following criteria: 
• they induce clinical signs or symptoms,  
• they are considered clinically significant,  
• they require therapy.  
Clinically significant abnormal laboratory values or test results should be identified through a 
review of values outside of normal ranges/clinical ly notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non- typi[INVESTIGATOR_90160]. Investigators have the responsibility for managing the safety of individual patient and identifying adverse events. Alert ranges for labs and other test abnormalities are included in Appendix 1. 
Adverse events should be recorded in the Adverse Events CRF under the signs, symptoms or 
diagnosis associated wit h them accompanied by [CONTACT_6644]. 
• the severity grade  
• mild: usually transient in nature and generally not interfering with normal activities  
• moderate: sufficiently discomforting to interfere with normal activities  
• severe: prevents normal act ivities  
• its relationship to the  (select what is applicable)  
study treatment (no/yes), or investigational treatment (no/yes), or  
the other study treatment(non-investigational) (no/yes), or both or indistinguishable, 
• its duration (start and end dates) or if the event is ongoing an outcome of not recovered/not resolved should be reported. 
• whether it constitutes a serious adverse event (SAE)  
• action taken regarding investigational treatment  
[COMPANY_001]  Confidential  Page 60  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 • whether other medication or therapi[INVESTIGATOR_95254] (concomitant medication/non-drug 
therapy)  
• its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving, recovered/resolved with sequelae; fatal; or unknown) 
An SAE is any adverse event (appearance of (or worsening of any pre- existing) undesirable 
sign(s), symptom(s) or medical conditions(s) which meets any one of the following criteria  
• is fatal or life -threatening  
• results in persistent or significant disability/incapacity  
• constitutes a congenital anomaly/birth defect  
• requires inpatient hospi[INVESTIGATOR_1081], unless hospi[INVESTIGATOR_062] : 
• routine treatment or monitoring of the studied indication, not associated with any deterioration in condition 
• elective or pre- planned treatment for a pre -existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent  
• treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063]  
• social reasons and respi[INVESTIGATOR_064]’s general condition  
• is medically significant, i.e. defined as an event that jeopardizes the patient or may require medical or surgical intervention to prevent one of the outcomes listed above.  
All malignant neoplasms will be assessed as serious under “medically significant” if other seriousness criteria are not met.  
Unlike routine safety assessments, SAEs are monitored continuously and have special reporting requirements; see Section 7.2. 
All adverse events should be treated appropriately. Treatment may include one or more of the following: no action taken (i.e. further observation only); [study/investigational] (select)  
treatment dosage adjusted/temporarily interrupted; study drug(s) permanently discontinued; concomitant medication given; non- drug therapy given. The action taken to treat the adverse 
event should be recorded on the Adverse Event CRF.  
Once an adverse even t is detected, it should be followed until its resolution or until it is judged 
to be permanent, and assessment should be made at each visit (or more frequently, if necessary) 
of any changes in severity, the suspected relationship to the investigational tr eatment , the 
interventions required to treat it, and the outcome. 
Information about common side effects already known about the investigational drug can be 
found in the Investigator Brochure (IB) or will be communicated between IB updates in the form of In vestigator Notifications. This information will be included in the patient informed 
consent and should be discussed with the patient during the study as needed. 
The investigator should also instruct each patient to report any new adverse event (beyond the 
protocol observation period) that the patient, or the patient’s personal physician, believes might 
[COMPANY_001]  Confidential  Page 61  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 reasonably be related to study treatment. This information should be recorded in the 
investigator’s source documents, however, if the AE meets the criteria of an SAE, it must be reported to [COMPANY_001]. 
7.[ADDRESS_604669] be reported to [COMPANY_001] within 24 hour s of learning of its occurrence:   
• after the subject has provided informed consent and until [ADDRESS_604670] has stopped the study 
participation (defined as last visit of the study at Week 268) for subjects who don’t enter follow -up 2 period  
• after the subject has provided informed consent and until the last telephone contact [CONTACT_471749]-up [ADDRESS_604671] be submitted within 24 hours of the investigator receiving the follow -up information. An SAE that is 
considered completely unrelated to a previously reported one should be reported separately as a new event.  
Information about all SAEs (either initial or follow up information) is collected an d recorded 
in English on the paper Serious Adverse Event Report Form or the electronic Serious Adverse Event Form within the OC/RDC system (where available). The Investigator must assess the relationship to each specific component of the study treatment (if the study treatment consists of several components).  
SAEs (initial and follow -up) that are recorded on the paper SAE form  should be faxed within 
[ADDRESS_604672] be kept with the case report form documentation at the study site. Follow- up information should 
be provided using a new paper SAE Report Form stating that this is a follow -up to a previously 
reported SAE   
SAEs (initial and follow -up) that are recorded electronically  in the OC/RDC system should be 
entered, saved and e- signed within 24 hours of awareness of the SAE  or changes to an 
existing SAE. These data will automatically be submitted to [COMPANY_001] Drug Safety & 
Epi[INVESTIGATOR_471714] r signature [INVESTIGATOR_1660] [ADDRESS_604673] .  
Follow- up information provided should describe whether the event has resolved or continues, 
if and how it was treated, whether the treatment code was broken or not and whether the patient continued or withdrew from study participation. Each re -occurrence, complication, or 
[COMPANY_001]  Confidential  Page 62  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 progression of the original event should be reported as a follow -up to that event regardless of 
when it occurs. 
If the SAE is not previously documented in the Investigator’s B rochure or Package Insert (new 
occurrence) and is thought to be related to the investigational treatment a Drug Safety and 
Epi[INVESTIGATOR_187869]. Nova rtis may need to issue an Investigator 
Notification (IN) to inform all investigators involved in any study with the same investigational treatment that this SAE has been reported.  Suspected Unexpected Serious Adverse Reactions 
(S[LOCATION_003]Rs) will be collected an d reported to the competent authorities and relevant ethics 
committees in accordance with Directive 2001/20/EC or as per national regulatory requirements in participating countries.  
7.3 Liver safety monitoring 
To ensure patient safety and enhance reliability i n determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of liver events has to be followed.  
Liver events are divided into two categories: 
• Liver events of special interest (AE SI) which consist of LFTs elevations 
• Medically significant liver events which are considered as serious adverse events (SAEs) 
and which consist of marked elevations of LFTs and / or pre- specified adverse events.  
Please refer to Table 14 -1 in Appendix 2 for complete definitions of liver events.  
Any liver event which meets the criteria for “ medically significant ” event as outlined in Table 
14-[ADDRESS_604674] procedures for SAE reporting  as described 
in Section 7.2.  
Every liver event as defined in Table 14-1 of Appendix 2 should be followed up by [CONTACT_471750]. Detailed information 
is outlined in Table 14 -2 in Appendix 2. 
• Repeating the LFT to confirm elevation as appropriate  
• Discontinuation of the investigational drug if appropriate 
• Hospi[INVESTIGATOR_18539] 
• A causality assessment of the liver event via exclusion of alternative causes (e.g., disease, co-medications)  
• An investigation of the liver event which needs to be followed until resolution.  
These investigations can include serology tests, imaging and pathology assessments, hepatologist’s consultancy, based on investigator’s discretion. All follow -up information, and 
the procedures performed should be recorded on appropriate CRF pages, including the liver event overview CRF pages. 
7.[ADDRESS_604675] be reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy should be 
[COMPANY_001]  Confidential  Page 63  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 followed up to determine outcome, including spontaneous or voluntary termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. 
Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported by [CONTACT_90210][INVESTIGATOR_066]. Pregnancy follow- up should be recorded on the same form and should include an assessment of the 
possible relationship to the study treatment  
Any SAE experienced durin g pregnancy must be reported on the SAE Report Form. 
7.5 Prospective suicidality assessment  
Not applicable.   
8 Data review and database management  
8.1 Site monitoring 
Before study initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] representative will review the protocol and CRFs with the investigators and their staff. During 
the study, the field monitor will visit the site regularly to check the completeness of patient records, the accuracy of entries on the CRFs, the adherence to the protocol and to Good Clinical 
Practice, the progress of enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Key study personnel must be available to assist the field monitor during these  visits.  
The investigator must maintain source documents for each patient in the study, consisting of case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical information, laboratory data, electrocardiograms, and the res ults of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the patient's file. The investigator must also keep the original informed consent form signed by [CONTACT_102] (a signed copy is given to the patie nt). 
The investigator must give the monitor access to all relevant source documents to confirm their consistency with the CRF entries. [COMPANY_001] monitoring standards require full verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all primary variables. Additional checks of the consistency of the source data with the CRFs are performed according to the study -specific 
monitoring plan. No information in source documents about the identity of the patients will be disclosed. 
8.2 Data collection 
Designated investigator staff will enter the data required by [CONTACT_109051]/RDC system. Designated investigator site staff will not be given access to the system until they have been trained.  
Automatic validation procedures within the system check for data discrepancies during and 
after data entry and, by [CONTACT_105273], allow the data to be confirmed 
[COMPANY_001]  Confidential  Page [ADDRESS_604676] certify that 
the data entered into the electronic Case Report Forms are complete and accurate. After 
database lock, the investigator will receive copi[INVESTIGATOR_314192].  
8.3 Database management and quality control 
[COMPANY_001] staff (or CRO working on behalf of [COMPANY_001]) review the data entered into the CRFs by [CONTACT_109052]. Queries are sent to the investigational site using an 
electronic data query. Designated investigator site staff is required to respond to the query and confirm or correct the data. If the electronic query system is not used, a pap er Data Query Form 
will be faxed to the site. Site personnel will complete and sign the faxed copy and fax it back to [COMPANY_001] staff that will make the correction to the database. The signed copy of the Data Query Form is kept at the investigator site.  
Concomitant medications entered into the database will be coded using the WHO Drug Reference List, which employs the Anatomical Therapeutic Chemical classification system. Concomitant procedures, non- drug therapi[INVESTIGATOR_90162] (MedDRA) terminology.  
Laboratory samples will be processed centrally and the results will be sent electronically to [COMPANY_001] (or a designated CRO).  
ECG readings will be processed centrally and the results will be  sent electronically to [COMPANY_001] 
(or a designated CRO).  
Randomization codes and data about all study drug(s) dispensed to the patient and all dosage changes will be tracked using an Interactive Response Technology (IRT). The system will be supplied by a vendor, who will also manage the database. The database will be sent electronically to [COMPANY_001] (or a designated CRO).  
Each occurrence of a code break via IRT will be reported to the clinical team and monitor.  The code break functionality will remain availa ble until study shut down or upon request of 
[COMPANY_001]. 
8.4 Data Monitoring Committee 
A data monitoring committee (DMC) may review the safety data of this trial at selected time intervals. If needed, details regarding the DMC process will be available in relevant secukinumab DMC charter. 
8.5 Adjudication Committee 
Not required. 
9 Data analysis  
Treatment groups for analysis will include: 
• Secukinumab 150 mg fixed interval 
[COMPANY_001]  Confidential  Page 65  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 • Secukinumab 300 mg fixed interval 
• Secukinumab 150 mg start of relapse 
• Secukinumab 300 mg start of r elapse  
• Secukinumab 300 mg open- label  
• Secukinumab 300 mg open- label switch  
9.1 Analysis sets  
Randomized set : The randomized set will be defined as all subjects who were randomized in 
core studies and who entered this extension study. 
Full analysis set (FAS) : The FAS will be comprised of all subjects entered the study. Following 
the intent -to-treat principle, subjects will be analyzed according to the treatment assigned to at 
randomization in core study. If the actual stratum is different to the assigned stratum in IRT, 
the actual stratum will be used in analyses.  
Safety set : The safety set includes all subjects who took at least one dose of study treatment 
during the treatment period. Subjects will be analyzed according to treatment received. 
9.[ADDRESS_604677].  
Psoriasis specific medical history will be summarized by [CONTACT_1570]. Previous treatments for psoriasis and whether or not response was achieved will be summarized by [CONTACT_1570].  
All the medical history information will be retrieved from the core studies.  
[COMPANY_001]  Confidential  Page 66  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 9.3 Treatments 
Study treatment 
The analysis of study treatment data will be based on the safety set.  
The duration of exposure to study treatment will also be summarized by [CONTACT_1570]. In 
addition, the number and percentage of subjects with cumulative exposure levels (e.g., any 
exposure, <4 weeks, ≥ 4 weeks, ≥ 8 weeks, etc.) will be presented. 
Prior and concomitant medication  
Prior and concomitant medic ations will be summarized in separate tables by [CONTACT_1570].  
Prior medications are defined as treatments taken and stopped prior to first dose of study 
treatment. Any medication given at least once between the day of first dose of randomized study treatment and the date of the last study visit will be a concomitant medication, including those which were started pre -baseline and continued into the period where study treatment is 
administered.  
Medications will be presented in alphabetical order, by [CONTACT_471751] 
(ATC) codes and grouped by [CONTACT_121975]. Tables will show the overall number and percentage of subjects receiving at least one treatment of a particular ATC code and at least one treatment in a particular anatomical  main group.  
Significant prior and concomitant non- drug therapi[INVESTIGATOR_471715].  
The number and percentage of subjects receiving different classes of prior psoriasis therapy (biologic systemic therapy, non -biologic systemic therapy, topi[INVESTIGATOR_2855], phototherapy, 
photochemotherapy) will be presented by [CONTACT_144971][INVESTIGATOR_471716] (primary lack of efficacy, secondary lack of ef ficacy, 
lack of tolerability, other) and the total duration of exposure to psoriasis therapi[INVESTIGATOR_144931]. 
Prior concomitant medications will be retrieved from the core studies.  
9.4 Analysis of the primary and key secondary variable(s) 
The primary analysis will focus on safety variables, please refer to Section 9.5.2. There are no 
other key secondary variables assessed in this study. 
9.4.1  Variable(s)  
Not Applicable 9.4.2  Statistical model, hypothesis, and method  of analysis 
Not applicable 
[COMPANY_001]  Confidential  Page 67  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 9.4.3  Handling of missing values/censoring/discontinuations  
Missing values in efficacy analyses, except for maintenance of response will not be imputed. 
All analyses will be based on observed values only. 
For maintenance of response, please see definition below, missing values with respect to 
response variables based on PASI score score will be imputed with non- response regardless to 
the reason for missing data (e.g. premature study discontinuation, missed visit, administrative 
issues) . Following the intent -to-treat principle for subjects who prematurely discontinue 
treatment, but who are observed in the follow -up period, efficacy data collected in follow -up 
periods will be linked to planned but missed study visits as well, following imputation schemes described in the analysis plan. 
Subjects who opt to change treatment regimen or dose level and move into open- label treatment 
with 300 mg s.c. secukinumab every four weeks for the remainder of the trial will be considered 
as non-responders in the analysis of maintenance of response. 
For other efficacy analyses they will not be considered after the timepoint of switching. 
9.4.4  Supportive analyses  
Not applicable 
9.5 Analysis of secondary variables  
9.5.1  Efficacy variables  
Maintenance of response 
Maintenance of response will be defined analogously as in the primary endpoint in 
CAIN457A2304, but for week 104 and 156, i.e. PASI 75 response 
• at Weeks 104 and 156, for subjects in the fixed interval regimens, or 
• at Weeks 92 and 144, for subjects in the retreatment at start of relapse regimen who do not 
require active treatment at Week 92 or 144, respectively, or 
• at Weeks 104 and 156, for subjects in the retreatment at start of relapse regimen who do require active treatment at Week 92 or 144, respectively. 
Summary s tatistics for maintenance of response at Week 104 and 156 will be presented in 
contingency tables and will include absolute and relative frequencies. Confidence intervals for response rates will be derived as well based on the score method including continuity correction (Newcombe 1998).  
PASI  50, PASI  75, PASI  90, PASI 100 and IGA 0 or 1 response over time 
Summary statistics for PASI  50, PASI  75, PASI  90, PASI  100 and IGA 0 or 1 response by [CONTACT_471752]. 
Confidence intervals for response rates will be derived as well based on the score method including continuity correction ( Newcombe, 1998 ). 
PASI score ov er time  
[COMPANY_001]  Confidential  Page 68  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 Summary statistics will be provided for absolute PASI scores as well as for percent change from 
baseline by [CONTACT_3232]. Figures will also be provided. 
IGA mod 2011 score over time Summary statistics for the IGA mod 2011 score over ti me will be presented by [CONTACT_279894].  
Relapse The number and percentage of subjects experiencing relapse will be presented by [CONTACT_10663].  
Rebound  
Rebound is defined as a worsening of PASI of > 125% of the v alue at baseline (core study), or 
new pustular, erythrodermic or more inflammatory psoriasis occurring within 8 weeks of stoppi[INVESTIGATOR_7374] (i.e., if this definition is fulfilled at more than [ADDRESS_604678] study treatment administration, this is not def ined as rebound). The number and percentage of subjects 
experiencing rebound will be presented by [CONTACT_3232]. 
9.5.[ADDRESS_604679] study treatment.  
With the exception of adverse events that qualify as "treatment emergent" (see definition above), data collected from telephone visits and unscheduled visits in follow -up period 2 will 
only be included in individual patient listings, but not in summary tables. 
AEs will be summarized by [CONTACT_1601], for each treatment group, the number and percentage 
of subjects having any AE, having an AE in each primary system organ class and having each individual AE (preferred term). Summaries will also be presented for AEs by [CONTACT_109056]. If a subject reported more than one adverse event with the same preferred term, the adverse event with the greatest severity will be presented. If a subject reported more than one adverse event within the same primary system organ class, the subject 
will be counted only once with the greatest severity at the system organ class level, where applicable.  
Confidence intervals for relative frequencies will be derived as well according to the score method including continuity correction by [CONTACT_85691], 1998. 
Separate summaries will be provided for death, serious adverse event, other significant adverse 
events leading to discontinuation and adverse events leading to dose adjustment (including study treatment discontinuation).  
A graphical display of relative frequencies within system organ classes and relative risks, if appropriate, will be presented.   
[COMPANY_001]  Confidential  Page 69  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 For infections, time -to-event analysis will be done. Results will be tabulated and the Kaplan -
Meier estimates for the cumulative rate will be plotted.    
Additional analyses will be provided for adjudicated adverse events.   
In supplementary analyses, exposure (or observation) -time adjusted analyses in terms of 
incidence rate and event rate will be provided.    
Laboratory data The summary of laboratory evaluations will be presented for three groups of laboratory tests 
(hematology, serum chemistry and urinalysis). Descriptive summary statistics for the change from baseline to each study visit will be presented. These descriptive summaries will be 
presented by [CONTACT_109057], laboratory test and treatment group. Change from baseline will only be summarized for subjects with both baseline and post baseline. 
For each param eter, the maximum change from baseline within each study period will be 
analyzed analogously.  
In addition, shift tables will be provided for all parameters to compare a subject’s baseline 
laboratory evaluation relative to the visit’s observed value. For the shift tables, the normal laboratory ranges will be used to evaluate whether a particular laboratory test value was normal, low, or high for each visit value relative to whether or not the baseline value was normal, low, or high. These summaries will be presented by [CONTACT_471753] -baseline.  
Immunogenicity  
Summary statistics for baseline, each post- baseline visit and change from baseline to each visit 
will be provided. Summary statistics will be provided for the percent of subjects with 
immunogenicity. If appropriate, shift tables will also be presented. 
Vital signs  
Analysis of the vital sign measurements using summary statistics for the change from baseline 
for each post -baseline visit will be  performed. These descriptive summaries will be presented 
by [CONTACT_37297]. Change from baseline will only be summarized for subjects with both baseline and post- baseline values.  
ECG  
Summary statistics will be presented for ECG variables b y visit and treatment group. 
9.5.3  Resource utilization  
Not applicable 
9.5.4  Health -related Quality of Life  
Summaries will be based on the FAS and will be presented separately for study periods (i.e., 
treatment period and follow-up period) if not specified otherwise.  
EQ-5D  
[COMPANY_001]  Confidential  Page 70  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 The EQ -5D is a questionnaire with 5 questions (regarding mobility, self -care, usual activities, 
pain/discomfort, and anxiety/depression) each with three categories (no problem, moderate 
problem, severe problems) and a health state assessment from 0 (worst possible health state) to 
100 (best possible health state). The number and percentage of subjects in each of the three categories for each question will be presented by [CONTACT_3232]. Summary statistics will be shown for the health stat e assessment by [CONTACT_3232].  
DLQI
©   
The DLQI measures functional disability of subjects with dermatological disorders that are greater than 18 years of age and had been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials.  The DLQI is a simple, validated, self -
administered 10- item questionnaire.  The instrument contains six functional scales (i.e., 
symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment).  For the DLQI, each question will be answered with the following response: “not at all,” “a little,” “a lot,” or “very much”. Seven scores will be derived from the DLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.  
For each of the seven scores the percentage change from baseline will be derived. Summary statistics will be provided for absolute values as well as for the percentage change by [CONTACT_3232].  
In addition, summary statis tics will be provided for number of subjects achieving DLQI 0 or 1.  
HAQ
©-DI (for subjects with PsA at baseline of the core study)  
Summary statistics will be derived for HAQ©-DI score over time for all subjects with psoriatic 
arthritis recorded on the Psor iatic Arthritis History eCRF at screening visit of the core study. 
Absolute and relative frequencies for HAQ©-DI response will also be presented. HAQ©- DI 
response is defined by [CONTACT_471754] 0.[ADDRESS_604680] deviation, coefficient of variation, median and quartiles, the geometric mean and geometric coefficient of variation and n(log) will be presented.  
   
  
 
     

[COMPANY_001]  Confidential  Page 71  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
  
 
 
9.5.7  B
iomarkers  
Not applicable.  
9.5.8  PK/PD  
Not applicable.  
   
9.[ADDRESS_604681] been unblinded at that stage, this interim analysis will also be unblinded. Of note, investigators, subjects and site staff will remain blinded to individual treatment group assignments.  
Further interim analyses, as regarded appropriate, can be conducted (e.g., for regulatory or publication purposes). 
9.7 Sample size calculation  
Study CAIN457A2304 planned to randomize 918 subjects. Assuming that 5% of the subj ects 
drop-out up to Week 12, and further 15% drop-out in CAIN457A2304 or CAIN457A2307 it is estimated that about 740 subjects will be eligible to enter this study. Assuming that the PASI 75 response rate at Week 12 in CAIN457A2304 is 80% and under the assumed drop- out rates 
above, about [ADDRESS_604682] one occurrence of an 
AE with a crude  incidence of 0.1% is about 14% and with a crude incidence of 1% is about 
77%. 
10 Ethical considerations  
10.1 Regulatory and ethical compliance 
This clinical study was designed and shall be implemented and reported in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC, US Code of Federal Regulations Title 21, and Japanese Ministry of Health, Labor, and Welfare), and with the ethical principles laid down in the Declaration of Helsinki. 

[COMPANY_001]  Confidential  Page 72  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 10.2 Informed consent procedures 
Eligible patients may only be included in the study after providing written (witnessed, where 
required by [CONTACT_6617]), IRB/IEC -approved informed consent, or, if incapable of doing 
so, after such consent has been provided by a legally acceptable representative of the patient. In cases where the patient’s representative gives consent, the patient should be informed about 
the study to the extent possible given his/her understanding. If the patient is capable of doing 
so, he/she should indicate assent by [CONTACT_90218] a separate assent form. Informed consent must be obtained before conducting any study- specific procedures (i.e. all of the procedures described in the protocol). The process of 
obtaining informed consent should be documented in the patient source documents.  
[COMPANY_001] will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP  guideline and regulatory requirements and is considered 
appropriate for this study. Any changes to the proposed consent form suggested by [CONTACT_90219]/IEC, and a copy of the approved version must be provided to the [COMPANY_001] monitor after IRB/IEC approval. 
10.3 Responsibilities of the investigator and IRB/IEC 
The protocol and the proposed informed consent form must be reviewed and approved by a properly constituted Institutional Review Board/Independent Ethics Committee/Research Ethics Board (IRB/IEC) before study start. A signed and dated statement that the protocol and informed consent have been approved by [CONTACT_1201]/IEC must be given to [COMPANY_001] before study initiation. Prior to study start, the investigator is required to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol and to give access to all relevant data and records to [COMPANY_001] monitors, auditors, [COMPANY_001] Clinical Quality Assurance representatives, designated agents of [COMPANY_001], IRBs/IECs, and regulatory authorities as required. If an inspection of the clinical site is requested by a regulatory authority, the inves tigator must inform 
[COMPANY_001] immediately that this request has been made.  
10.4 Publication of study protocol and results 
[COMPANY_001] assures that the key design elements of this protocol will be posted in a publicly accessible database such as clinicaltrials.gov. In addition, upon study completion and 
finalization of the study report the results of this trial will be either submitted for publication and/or posted in a publicly accessible database of clinical trial results.  
[ADDRESS_604683] 
be considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_471755]/IEC it cannot be implemented. All significant protocol deviations will 
be recorded and reported in the CSR. 
11.[ADDRESS_604684] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC. Only amendments that are required for patient safety may be implemented prior to IRB/IEC approval. Notwithstanding the need for approval of formal protocol amendments, the investigator is expect ed to take any immediate action required for the safety of any patient included in this 
study, even if this action represents a deviation from the protocol. In such cases, [COMPANY_001] should be notified of this action and the IRB/IEC at the study site should be informed within [ADDRESS_604685]  
Chobanian AV, Bakris GL, Black HR (2003) Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension; 42:1206–1252. 
Committee for medicinal products for human use (CHMP), European Medicines Agency for 
the Evaluation of Medicines for Human Use (2001) Guideline for choice of control group in clinical Trials.   CPMP/ICH/364/96 corr document. London, [LOCATION_006]. 
Committee for medicinal products for human use (CHMP), European Medicines Agency for 
the Evaluation of Medicines for Human Use (2004) Guideline on clinical investigation of 
medicinal products indicated for the treatment of psoriasis. CHMP/EWP/2454/02 corr document. London, [LOCATION_006].  
Fredriksson T and Pettersson U (1978) Severe psoriasis-oral therapy with a new retinoid. Dermatologica; 157:238-44. 
Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI): A simple  practical 
measure for routine clinical use. Clin Exp Dermatol; 19:210–216. Gottlieb A, Griffiths CEM, Ho VC, et al (2005) Efficacy and tolerability of oral pi[INVESTIGATOR_109005]: a double-blind, 
multicentre, randomized dose-finding trial. Br J Dermatol; 152:1219-27. 
Lohman TG, [COMPANY_002] AF, (1988) Anthropometric standardization reference manual. Martoral 
R(eds) Champaign, IL: Human Kinetics. 
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, et al. (2007) Guidelines for the 
Management of Arterial Hypertension: The Task Force for the Management of Arterial 
[COMPANY_001]  Confidential  Page 74  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 Hypertension of the European Society of Hypertension (ESH) and of the European Society of 
Cardiology (ESC). J Hypertens; 25:1105–1187. 
Newcomb e RG (1998) Two-sided confidence intervals for the single proportion: comparison 
of seven methods. Statistics in Medicine; 17: 857-872.  Weisman S, Pollack CR, Gottschalk RW (2003) Psoriasis disease severity measures: 
comparing efficacy of treatments for s evere psoriasis. J Dermatolog Treat; 14:158-165. 
WHO regional office for Europe, Nutrition Unit. (1988) Classification and description of 
anthropometric data. EUR/ICP/NUT/125 document. Copenhagen, Denmark. 
[COMPANY_001]  Confidential  Page 75  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 13 Appendix 1: Clinically notable laboratory values a nd vital 
signs  
The following criteria will be used to define expanded limits and notable abnormalities of key 
laboratory tests. Notable values for blood pressure and pulse are presented in Section 6.5.[ADDRESS_604686]. No specification is foreseen as part of the study protocol. 
 Liver Function and Related Variables  
Alanine transaminase (ALT) (SGPT):  > 3 x Upper Limit of Normal (ULN)  
Aspartate transaminase (AST) (SGOT):  > [ADDRESS_604687]  
Total bilirubin:     > [ADDRESS_604688]  
Alkaline phosphatase:    > 2.[ADDRESS_604689] Renal Function and Electrolyte Variables  
Creatinine (serum):     > 1.[ADDRESS_604690]  
Potassium:      > 6 mmol/L or < 3 mmol/L 
Sodium:      > 160 mmol/L or < 115 mmol/L Hematology Variables Hemoglobin:      ≥ 20 g/dL decrease from baseline Platelet count:     < Lower Limit of Normal (LLN)  
White blood cell count:    < 0.[ADDRESS_604691] Neutrophils:      < 0.[ADDRESS_604692] Eosinophils:      > 1.[ADDRESS_604693] Lymphocytes:      > 1.[ADDRESS_604694] Urinalysis Variable  
Protein urine dipstick:    ++* 
 * ++ is ≥ 100 mg/dL 
[COMPANY_001]  Confidential  Page 76  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 14 Appendix 2: Liver event definitions and follow -up 
requirements  
Table 14-1 Liver Event Definit ions 
 Definition/ threshold  
Adverse event of special 
interest   
Laboratory values  ALT or AST > [ADDRESS_604695]  
 ALP > [ADDRESS_604696]  
 TBL > 1.[ADDRESS_604697]  
Medically significant event 
(SAE)   
Laboratory values  ALT or AST > [ADDRESS_604698] (with or without TBL > [ADDRESS_604699] [mainly 
conjugated fraction])  
 ALP > [ADDRESS_604700] (with or without TBL > [ADDRESS_604701] [mainly conjugated 
fraction])  
 TBL > [ADDRESS_604702]  
 Potential Hy’s Law cases (defined as ALT/AST > [ADDRESS_604703] and 
TBL > [ADDRESS_604704] [mainly conjugated fraction] without  notable 
increase in ALP to > [ADDRESS_604705])  
Adverse events  Any clinical event of jaundice (or equivalent term)  
 ALT or AST > [ADDRESS_604706] accompanied by [CONTACT_352003], fatigue, 
abdominal pain, nausea, or vomiting, or rash with eosinophilia  
 Any event that links  to a preferred term (PT) in the MedDRA 
dictionary falling under the SMQ sub- module “Drug- related hepatic 
disorders – severe events only”* or any “Hy’s law case” PT  
* These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage-related 
conditions; the non -infectious hepatitis; the benign, malignant and unspecified liver neoplasms  
 
  
[COMPANY_001]  Confidential  Page 77  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 Table 14-2 Liver Event Follow Up Requirements  
Criteria  Event type  Actions required  Follow -up monitoring  
Potential Hy’s Law 
casea Medically significant  Discontinue the study drug immediately  
Hospi[INVESTIGATOR_18552], if clinically 
appropriate  
Report to [COMPANY_001] as an SAE  
Establish causality  ALT, AST, TBL, Alb, PT, 
ALP and γGT until resolution
c (frequency at 
investigator discretion)  
 
ALT or AST  
> [ADDRESS_604707], TBL, Alb, PT, 
ALP and γGT until resolution
c (frequency at 
investigator discretion)  
> 5 to ≤ [ADDRESS_604708], TBL, Al b, PT, 
ALP and γGT until resolution
c (frequency at 
investigator discretion)  
> [ADDRESS_604709], TBL, Alb, PT, 
ALP and γGT until resolution
c (frequency at 
investigator discretion)  
> 3 to ≤ [ADDRESS_604710]  
(patient is asymptomatic)  AESI  Central laboratory to report to Investigator & [COMPANY_001]  
Repeat LFT once or twice in the 
week  
If elevation persists, establish 
causality  Investigator discretion  
Monitor LFT within 1 to 4 
weeks or at next visit  
≤ [ADDRESS_604711]  
(patient is 
asymptomatic)  N/A Repeat LFT at next visit   
ALP (isolated)  
> [ADDRESS_604712]  Medically significant  Repeat LFT within 48 hours  
If elevation persists, report to 
[COMPANY_001] as an SAE  
Establish causality  Investigator discretion  
Monitor LFT within 1 to 4 weeks or at next visit  
> 2 to ≤[ADDRESS_604713]  
(patient is 
asymptomatic)  AESI  Central laboratory to report to Investigator & [COMPANY_001]  Investigator discretion  
Monitor LFT within 1 to 4 
weeks or at next visit  
[COMPANY_001]  Confidential  Page 78  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 Criteria  Event type  Actions required  Follow -up monitoring  
Repeat LFT once or twice in the 
week If elevation persists, 
establish causality  
≤ [ADDRESS_604714]  
(patient is 
asymptomatic)  N/A Repeat LFT at next visit   
TBL (isolated)  
> [ADDRESS_604715], TBL, Alb, PT, 
ALP and γGT until 
resolution
c (frequency at 
investigator discretion)  
Test for hemolysis (e.g., reticulocytes, haptoglobin, unconjugated [indirect] 
bilirubin)  
> 1.5 to ≤ [ADDRESS_604716]  
(patient is asymptomatic)  AESI  
Central laboratory to report to 
[COMPANY_001]  
Repeat LFT once or twice in the 
weekIf elevation persists, 
establish causality  investigator discretion  
Monitor LFT within 1 to 4 weeks or at next visit  
≤ 1.[ADDRESS_604717]  
(patient is 
asymptomatic)  N/A Repeat LFT at next visit   
Preferred terms  
Jaundice  Medically 
significant  Discontinue the study  drug 
immediately  
Hospi[INVESTIGATOR_471717], AST, TBL, Alb, PT, 
ALP and γGT until resolution
c (frequency at 
investigator discretion)  
“Drug -related 
hepatic disorders - severe 
events only” SMQ AE Medically 
significant  Discontinue the study drug  
hospi[INVESTIGATOR_471718]  
a Elevated ALT/AST > [ADDRESS_604718] and TBL > [ADDRESS_604719] but with no notable increase in ALP to > [ADDRESS_604720]  
b General malaise, fatigue, abdominal pain, nausea, or vomiting, rash with eosinophilia  
c Resolution is defined as an outcome of one of the following: return to baseline values, stable 
values at three subsequent monitoring visits at least 2 weeks apart, remain at elevated level after a 
maximum of 6 months, liver transplantation, and death.  
 
   
[COMPANY_001]  Confidential  Page 79  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 15 Appendix 3: Blood collection log for pharmacokinetics (PK) and 
immunogenicity (IG)  
Table 15-1 Blood collection log for PK  
Visit Name  [CONTACT_471760] 
(approx
.) Analyte  Sample number  Dose Reference ID/  
PK collection number** 
Week 521 Pre-dose  (2 mL)  AIN457 for 
PK (5) (5) 
Week 64  Pre-dose  2 mL  AIN457 for PK 7 7 
Week 76  Pre-dose  2 mL  AIN457 for PK 8 8 
Week 104  Pre-dose  2 mL  AIN457 for 
PK 9 9 
Week 116  Pre-dose  2 mL  AIN457 for PK 10 10 
Week 128  Pre-dose  2 mL  AIN457 for PK 11 11 
Week 156  Pre-dose  2 mL  AIN457 for 
PK 12 12 
Week 208  Pre-dose  2 mL  AIN457  for 
PK 13 13 
Week 260  672 hours*  2 mL  AIN457 for PK 14 14 
Week 268 
(F8) 2016 hours*  2 mL  AIN457 for PK 15 14 
1The data and sample numbering for Week 52 visit (enrollment) will have been collected as part of the 
end of maintenance visit (Week 52) from core study CAIN457A2304 or CAIN457A2307  
* Scheduled post -dose time points for sample numbers 14 and 15 ([ADDRESS_604721] -
dose, respectively) refer to the last dose given at Week 256 as time 0.  
** If a PK sample is collected at an unscheduled visit, the sample numbers will follow the pattern, 
1001, 1002, etc.  
[COMPANY_001]  Confidential  Page 80  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 Table 15-2 Blood collection log for IG  
Visit Name  [CONTACT_471760] 
(approx.)  Analyte  PK collection number** 
Week 521 Pre-dose  (2 mL)  anti-AIN457 for 
IG (504)  
Week 76  Pre-dose  2 mL  anti-AIN457 for 
IG 506 
Week 104  Pre-dose  2 mL  anti-AIN457 for 
IG 507 
Week 128  Pre-dose  2 mL  anti-AIN457 for 
IG 508 
Week 156  Pre-dose  2 mL  anti-AIN457 for 
IG 509 
Week 208  Pre-dose  2 mL  anti-AIN457 for 
IG 510 
Week 260  672 hours*  2 mL  anti-AIN457 for 
IG 511 
Week 268(F8)  2016 
hours*  2 mL  anti-AIN457 for 
IG 512 
1The data and sample numbering for Week 52 visit (enrollment) will have been collected as part of the 
end of maintenance visit (Week 52) from core study CAIN457A2304 or CAIN457A2307  
* Scheduled post -dose time points for sample numbers 511 and 512 ([ADDRESS_604722] -
dose, respectively) refer to the last dose given at Week 256 as time 0.  
** If an IG sample is collected at an unscheduled visit, the sample numbers will follow the pattern, 3001, 3002, etc.  
[COMPANY_001]  Confidential  Page 81  
Amendment Protocol v02 Clean   Protocol No. CAIN457A2304E1  
 
 16 Appendix 4: Pharmacokinetics (PK) and immunogenicity 
(IG) sample labeling information 
16.1.[ADDRESS_604723] be labeled as in the following  example and as provided by [CONTACT_471756]:  CAIN457A2304 E1 
Site: cccc  
(4 digits for the current site number)  
Subject:  
 
 
 Ccccrrr  
([ADDRESS_604724] number. Add ‘0’ ahead of the numbers 
if needed to obtain the correct number of total digits)  
Sample number:  As indicated in Table 15 -1 
Analyte:  AIN457 for PK  
Labels will be provided by [CONTACT_471757].  
As PK samples are managed by a central laboratory, no added label should cover the original 
label.  
16.1.[ADDRESS_604725] be labeled as in the following example and as provided by [CONTACT_471758]:  CAIN457A2304 E1 
Site: cccc  
(4 digits for the current site number)  
Subject:  Ccccrrr  
([ADDRESS_604726] number. Add ‘0’ ahead of the numbers 
if needed to obtain the correct number of total digits)  
Sample number:  As indicated in Table 15 -2  
Analyte:  anti-AIN457 for IG  
Labels will be provided by [CONTACT_471759].  
As IG samples are managed by a central laboratory, no added label should cover the original 
label.  
  